# Chapter 120: Other (or Unknown) Substance Withdrawal

Here is the comprehensive academic chapter on the biological and neurological basis of Other (or Unknown) Substance Withdrawal, citing exclusively from the provided research papers.

# Chapter X: The Biological and Neurological Basis of Other (or Unknown) Substance Withdrawal

## Introduction

The Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD) provide frameworks for understanding substance-related disorders, which encompass a wide range of psychoactive compounds including alcohol, caffeine, cannabis, hallucinogens, opioids, sedatives, stimulants, and tobacco (Daley & Douaihy, 2019; Kaplan et al., 1994). A crucial component of these disorders is the withdrawal syndrome, a cluster of signs and symptoms that manifest upon the cessation or reduction in the use of a substance to which an individual has developed physiological dependence (Franklin, 1995; Thompson, & Weber, 2021). While the withdrawal syndromes for many specific substances are well-characterized, clinical practice and forensic toxicology frequently encounter situations where the intoxicating substance is unknown, adulterated, or a novel psychoactive substance (NPS) not yet cataloged (Sarkar et al., 2023; Coman et al., 2019). This gives rise to the diagnostic category of "Other (or Unknown) Substance-Related Disorders" (Daley & Douaihy, 2019; Wakefield, 2015; Zagorski, 2022).

From a biological perspective, Other (or Unknown) Substance Withdrawal represents a state of profound neurophysiological dysregulation. Addiction is understood as a chronic, relapsing brain disease characterized by compulsive drug-seeking and use despite adverse consequences (Koob et al., 2015; Rodriguez et al., 2017; Stratyner, 2006). This process is driven by drug-induced adaptations in the brain's reward, motivation, and memory circuits (George & Koob, 2017; Roberts & Koob, 1997). Chronic exposure to any psychoactive substance that causes dependence leads the central nervous system (CNS) to adapt its homeostatic mechanisms to counteract the drug's persistent effects (Isbell & Fraser, 1950; Goldstein, 2001). Withdrawal, therefore, is the clinical manifestation of these adaptations being unmasked when the substance is removed (Goldstein, 2001; Thompson et al., 2021). The resulting state is often one of CNS hyperexcitability or dysfunction, producing symptoms that are typically opposite to the acute effects of the substance (Becker & Redmond, 2002; Yersin, 1999).

The clinical presentation of withdrawal from an unknown substance is inherently heterogeneous and can mimic a vast array of medical and psychiatric conditions, creating significant diagnostic challenges (Sarkar et al., 2023; Terman & Terman, 2013). Symptoms can range from mild anxiety, insomnia, and fatigue to severe and life-threatening complications such as seizures, delirium, and psychosis (Thompson & Weber, 2021; Khoury, 1968; Finer, 1971). The syndrome may be mistaken for a primary mood disorder, anxiety disorder, or psychotic illness, complicating effective management (Chouinard & Chouinard, 2015; Mihanović et al., 2009). For example, a patient presenting with agitation, confusion, and autonomic instability could be experiencing withdrawal from a sedative-hypnotic, intoxication with a stimulant, or a primary medical condition like infection or metabolic derangement (Nassisi et al., 2006; Bassetti, 2007).

This chapter aims to provide a comprehensive overview of the biological and neurological basis of Other (or Unknown) Substance Withdrawal. Lacking direct empirical data on "unknown" substances, this exploration will proceed by analogy, synthesizing principles derived from the study of known psychoactive agents. We will examine the neurobiological systems, genetic underpinnings, and cellular mechanisms that are broadly implicated in the development of dependence and withdrawal. By understanding these fundamental processes, we can construct a neurobiological framework for conceptualizing, assessing, and managing withdrawal syndromes even when the specific causative agent is not identified. This approach acknowledges that while the specific pharmacological targets may vary, the brain's adaptive responses to chronic psychoactive substance exposure follow common neurobiological pathways (Koob et al., 2015; George & Koob, 2017).

## Neurobiological Systems

The clinical manifestations of withdrawal from any substance, known or unknown, are the direct result of perturbations in the brain's complex neurobiological systems (Roberts & Koob, 1997). Chronic substance use forces the brain into a state of allostasis, where it establishes a new, pathological equilibrium in the presence of the drug (George & Koob, 2017). The sudden absence of the substance unmasks these compensatory changes, leading to a state of severe dysregulation across multiple neurotransmitter pathways and neural circuits (Goldstein, 2001; Yersin, 1999).

### Neurotransmitter Systems and Neuropharmacology

The specific withdrawal syndrome depends on the class of drug and its primary mechanism of action, but several key neurotransmitter systems are consistently implicated in the broader phenomena of dependence and withdrawal (Scuvée‐Moreau, 2013; Koob et al., 2008).

**The Dopaminergic System:** The mesolimbic dopamine system, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc), is a central component of the brain's reward circuitry (Koob et al., 2015; Tyler & Leggio, 2024). Virtually all drugs of abuse, regardless of their primary pharmacological target, increase dopamine release in the NAc, producing feelings of pleasure and euphoria that reinforce drug-taking behavior (Scuvée‐Moreau, 2013; Roberts & Koob, 1997; Velásquez-Martínez & Ortíz, 2014). Chronic overstimulation of this pathway leads to neuroadaptive changes, including a downregulation of the brain's reward systems (George & Koob, 2017). During withdrawal, this results in a hypodopaminergic state, manifesting as anhedonia (the inability to experience pleasure), dysphoria, apathy, and amotivation—symptoms that are core features of withdrawal from stimulants like cocaine and amphetamines but also contribute to the negative affective state seen in withdrawal from opioids and alcohol (Thompson & Weber, 2021; Rastegar & Fingerhood, 2015). This blunted reward function is a powerful driver of craving and relapse, as the individual seeks to restore the hedonic tone by resuming substance use (George & Koob, 2017; Jahan & Burgess, 2021). The involvement of dopamine extends to psychotic symptoms, as stimulant-induced psychosis is thought to involve dopaminergic hyperactivity, a mechanism that may also be relevant in withdrawal-related psychosis (Snyder, 2019; Hansell, 1975).

**GABA and Glutamate Systems:** The balance between the brain's primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), and its primary excitatory neurotransmitter, glutamate, is critical for maintaining CNS stability (Becker & Redmond, 2002). Many substances, particularly CNS depressants like alcohol, barbiturates, and benzodiazepines, enhance GABAergic transmission (Tseng et al., 2020; Thompson & Weber, 2021). The brain compensates for this chronic inhibition by downregulating GABA receptors and upregulating excitatory glutamate systems, particularly NMDA receptors (Becker & Redmond, 2002; Trujillo, 2002). Upon withdrawal, this balance is dramatically shifted toward a state of profound CNS hyperexcitability (Becker & Redmond, 2002; Yersin, 1999). This hyperexcitability is the neurobiological substrate for many of the most dangerous withdrawal symptoms, including anxiety, agitation, tremors, insomnia, autonomic hyperactivity, hallucinations, and life-threatening seizures and delirium tremens (Thompson & Weber, 2021; Becker & Redmond, 2002; Saitz, 1998). Pathophysiological perturbations in GABAergic and glutamatergic transmission have also been implicated in catatonia, a syndrome that can occur during withdrawal from certain substances, including alcohol (Zutshi et al., 2007; Yarlagadda et al., 2007; Mohr, 2022).

**Serotonergic and Noradrenergic Systems:** The serotonin (5-HT) and norepinephrine (NE) systems are deeply involved in regulating mood, anxiety, sleep, and arousal (Lane & Baldwin, 1997). Many psychoactive substances, including stimulants and hallucinogens, directly or indirectly modulate these systems (Scotton et al., 2019; Snyder, 2019). For example, MDMA ('ecstasy') causes a massive release and subsequent depletion of serotonin (Patel et al., 2011; Molero‐Chamizo, 2005). Withdrawal from various substances, including stimulants, alcohol, and opioids, is often characterized by a negative affective state that includes depression, anxiety, and irritability (Thompson & Weber, 2021; Hughes et al., 1994). This is thought to reflect dysregulation in serotonergic and noradrenergic pathways (Chouinard & Chouinard, 2015; Scotton et al., 2019). The serotonin syndrome, a potentially lethal toxidrome caused by excessive serotonergic activity, can be precipitated by interactions between prescribed antidepressants and recreational drugs, highlighting the critical role of this system in drug toxicity (Scotton et al., 2019; Lane & Baldwin, 1997; Rahmani, 2011). Discontinuation syndromes from antidepressants, which share features with substance withdrawal, are also mediated by changes in these systems (Chouinard & Chouinard, 2015; Howland, 2010).

**Opioid and Cannabinoid Systems:** The endogenous opioid and cannabinoid systems are key modulators of pain, mood, and reward (Noble & Roques, 2003; Chaouloff et al., 2013). Exogenous opioids (e.g., heroin, morphine) and cannabinoids (e.g., THC) produce their effects by acting on mu-opioid and CB1 receptors, respectively (Hosztafi, 2011; Pytell & Rastegar, 2025). Chronic use leads to receptor downregulation and other adaptations. Withdrawal from opioids is characterized by a severe syndrome including dysphoria, pain, nausea, diarrhea, and autonomic hyperactivity (Noble & Roques, 2003; Thompson & Weber, 2021). Cannabis withdrawal, now recognized as a discrete syndrome, involves irritability, anxiety, insomnia, and decreased appetite (Connor et al., 2021; Thompson & Weber, 2021; Roy‐Byrne, 2008). The increasing availability of potent synthetic cannabinoids and opioids means that clinicians are more likely to encounter severe and atypical withdrawal presentations related to these systems (Wojtyła-Buciora et al., 2023; Sweet et al., 2017).

### Brain Regions, Neural Circuits, and Functional Connectivity

Withdrawal is not the result of dysfunction in a single brain region but rather a network-level phenomenon involving interconnected circuits responsible for reward, stress, and executive control (George & Koob, 2017; Koob et al., 2015).

**The Extended Amygdala and Stress Circuits:** As addiction progresses, the motivation for drug use shifts from positive reinforcement (seeking pleasure) to negative reinforcement (avoiding the discomfort of withdrawal) (Jahan & Burgess, 2021; George & Koob, 2017). This shift is mediated by the recruitment of brain stress systems centered in the extended amygdala, which includes the bed nucleus of the stria terminalis (BNST) and the central nucleus of the amygdala (CeA) (George & Koob, 2017; Wand, 2008). During withdrawal, these circuits become hyperactive, driven by neurotransmitters like corticotropin-releasing factor (CRF) (Wand, 2008; Koob et al., 2021). This hyperactivity of the brain's "anti-reward" system is responsible for the negative emotional state of withdrawal, including anxiety, irritability, and dysphoria (George & Koob, 2017). This stress-induced state is a major driver of craving and relapse (Wand, 2008; Daley & Douaihy, 2019).

**The Prefrontal Cortex and Executive Function:** The prefrontal cortex (PFC) is crucial for executive functions, including decision-making, impulse control, and assigning salience to stimuli (George & Koob, 2017). Chronic drug use leads to hypofrontality, a state of reduced PFC activity and impaired functional connectivity with other brain regions (Bastos Vasconcelos et al., 2022; Ritz et al., 2012). During withdrawal, this impairment in top-down executive control contributes to poor impulse control, impaired judgment, and an inability to resist cravings, even in the face of severe negative consequences (George & Koob, 2017; Scuvée‐Moreau, 2013). The PFC's role in cognitive function also explains the difficulties in attention and concentration that are common symptoms of withdrawal from many substances (Hughes et al., 1994; Thompson & Weber, 2021).

**The Hippocampus and Insula:** The hippocampus is critical for memory, including the powerful associative memories that link drug use with specific environmental cues (Daley & Douaihy, 2019; Scuvée‐Moreau, 2013). Exposure to these cues can trigger intense cravings and relapse, a phenomenon mediated by conditioned learning pathways involving the hippocampus and amygdala (Daley & Douaihy, 2019; Baker & Kalivas, 2005). The insular cortex is involved in interoception—the awareness of the body's internal state—and is believed to play a key role in the subjective experience of craving and the conscious urge to use a drug (George & Koob, 2017). Dysfunction in these regions during withdrawal contributes to the overwhelming nature of cravings and the high risk of relapse (Baker & Kalivas, 2005).

Understanding the interplay of these systems is crucial when assessing a patient withdrawing from an unknown substance. A presentation dominated by CNS hyperexcitability (seizures, delirium) strongly suggests a withdrawal from a GABAergic agent (Thompson & Weber, 2021). A syndrome characterized primarily by profound anhedonia, fatigue, and psychomotor retardation points toward withdrawal from a stimulant (Rastegar & Fingerhood, 2015). A presentation with severe autonomic hyperactivity, pain, and gastrointestinal distress is characteristic of opioid withdrawal (Noble & Roques, 2003). However, given the rise of polysubstance use and novel synthetic drugs, withdrawal syndromes are often mixed and atypical, reflecting dysregulation across multiple neurobiological systems simultaneously (Sarkar et al., 2023; Coman et al., 2019).

## Genetic and Molecular Basis

The development of a substance use disorder (SUD) and the subsequent emergence of a withdrawal syndrome upon cessation are not inevitable consequences of substance exposure. There is significant individual variability in susceptibility, which is shaped by a complex interplay of genetic, environmental, and developmental factors (Koob et al., 2015; Wand, 2008). While direct genetic studies of "Other (or Unknown) Substance Withdrawal" are nonexistent, research into known substances provides a framework for understanding the heritable and molecular components that likely contribute to this vulnerability.

### Genetic Factors and Heritability

Addiction is recognized as a disease with a strong genetic component (Daley & Douaihy, 2019; Blum & Trachtenberg, 1988). Genetic factors are estimated to account for 40-60% of the vulnerability to addiction (Koob et al., 2021). This heritability does not imply a single "addiction gene" but rather reflects the cumulative influence of many genes that affect various neurobiological processes (Blum & Trachtenberg, 1988). These processes include the metabolism of drugs, the function of neurotransmitter receptors and transporters, signal transduction pathways, and the development of neural circuits involved in reward and stress (Tyler & Leggio, 2024; Wenbing et al., 2025).

Genetic predispositions can influence every stage of the addiction cycle (George & Koob, 2017). For example, variations in genes coding for alcohol-metabolizing enzymes can influence drinking behavior and the risk of developing alcohol use disorder (Blum & Trachtenberg, 1988). Similarly, polymorphisms in genes for dopamine receptors (Ereshefsky et al., 1990) or transporters may alter the rewarding effects of stimulants, influencing the transition from casual use to dependence (Koob et al., 2015). Genetic factors also contribute to personality traits such as impulsivity and sensation-seeking, which are themselves risk factors for substance use and the development of SUDs (Evren & Dalbudak, 2009; Smith et al., 2010).

It is plausible that these same genetic vulnerabilities contribute to the likelihood and severity of withdrawal from any substance, including unknown ones. An individual with a genetic predisposition toward a hypofunctional dopamine reward system or a hyperreactive brain stress system may be more susceptible to developing the profound anhedonia and anxiety characteristic of withdrawal (Blum & Trachtenberg, 1988; George & Koob, 2017). Family history of SUDs is a significant risk factor, suggesting a shared genetic liability that would apply regardless of the specific substance involved (Winters & Ingwalson, 2022; Rohde et al., 1991).

### Molecular Mechanisms

At the molecular level, withdrawal is the result of neuroplastic changes that occur in response to chronic drug exposure (Koob et al., 2015; Scuvée‐Moreau, 2013). These are not simply transient shifts in neurotransmitter levels but involve lasting alterations in gene expression, protein synthesis, and synaptic structure (Baker & Kalivas, 2005; Lee et al., 2025).

**Receptor Regulation:** A fundamental molecular adaptation is the change in the number and sensitivity of neurotransmitter receptors (Chouinard & Chouinard, 2015). Chronic exposure to a receptor agonist (like opioids or benzodiazepines) often leads to receptor downregulation and desensitization to reduce the drug's effect (tolerance) (Trujillo, 2002; Goldstein, 2001). Conversely, chronic exposure to a receptor antagonist leads to receptor upregulation. During withdrawal, the sudden absence of the drug leaves a system with a miscalibrated number of receptors, leading to the rebound hyperactivity or hypoactivity that characterizes the syndrome (Goldstein, 2001; Becker & Redmond, 2002). For example, withdrawal from a GABA agonist like alcohol unmasks a state of reduced GABAergic inhibition and enhanced glutamatergic excitation due to these receptor changes (Becker & Redmond, 2002; Thompson & Weber, 2021). Similar long-lasting receptor changes are observed after discontinuation of other CNS drugs like antidepressants, producing withdrawal phenomena (Chouinard & Chouinard, 2015).

**Signal Transduction and Gene Expression:** The effects of chronic drug use extend beyond the receptor to intracellular signal transduction pathways (Koob et al., 2021). One of the best-established molecular mechanisms of addiction involves the upregulation of the cyclic AMP (cAMP) second messenger pathway in response to chronic opiate administration (Antonio & Alfredo, 2012). This adaptation is thought to mediate aspects of tolerance and dependence. Changes in these pathways can alter the activity of transcription factors, such as CREB (cAMP response element-binding protein), which in turn modify the expression of genes involved in neuronal structure and function (Antonio & Alfredo, 2012; Koob et al., 2015). This process of drug-induced gene expression leads to the long-term, stable changes in synaptic strength and connectivity that underlie the persistence of withdrawal vulnerability and craving (Baker & Kalivas, 2005).

**Epigenetic Modifications:** Emerging research suggests that epigenetic mechanisms—modifications to DNA and its associated proteins that alter gene expression without changing the DNA sequence itself—play a crucial role in the long-lasting neuroadaptations of addiction (Amoah et al., 2022). Chronic drug use can induce changes such as DNA methylation and histone acetylation, which can persistently alter the expression of genes related to neuroplasticity, stress response, and reward. These epigenetic marks may help explain why vulnerability to relapse can persist for months or even years after the last drug use (Baker & Kalivas, 2005). It is highly probable that such mechanisms are at play in dependence on any substance, contributing to the enduring nature of the withdrawal syndrome and associated craving (Scuvée‐Moreau, 2013).

The molecular basis of withdrawal from an unknown substance would depend on its specific pharmacological target. A substance acting on GABA receptors would induce adaptations in that system, while one acting on dopamine transporters would primarily affect the dopamine system. However, the overarching principles of receptor regulation, altered signal transduction, and long-term changes in gene expression are likely universal mechanisms of dependence and withdrawal, providing a common molecular framework for understanding these syndromes regardless of the specific agent (Koob et al., 2015; George & Koob, 2017).

## Brain Structure and Function

The profound behavioral and psychological disturbances seen in Other (or Unknown) Substance Withdrawal are rooted in alterations of both brain function and, in some cases, brain structure (Brust, 2002; Hulse et al., 2005). Neuroimaging and neuropathological studies of known substances provide critical insights into the potential structural and functional abnormalities that may underlie withdrawal from any dependence-producing agent.

### Neuroimaging Findings

While specific neuroimaging studies on withdrawal from "unknown" substances are not available, findings from studies on known substances can be extrapolated to form a general model. Neuroimaging techniques can reveal both structural changes (e.g., via Computed Tomography [CT] and Magnetic Resonance Imaging [MRI]) and functional changes (e.g., via functional MRI [fMRI], Positron Emission Tomography [PET], and Diffusion Tensor Imaging [DTI]).

**Structural Imaging (CT and MRI):** Chronic abuse of certain substances, particularly alcohol, is associated with demonstrable structural brain changes, including cerebral atrophy and ventricular enlargement (Golden & Golden, 2004; Hulse et al., 2005). These changes reflect neuronal loss and are linked to the chronic cognitive impairments often seen in individuals with long-term substance use disorders (Sanz Cid, 1990; Hulse et al., 2005). While these changes are the result of chronic toxicity rather than acute withdrawal, they create a vulnerable neuroanatomical substrate upon which withdrawal unfolds. For example, a patient with pre-existing alcohol-related brain atrophy may be more susceptible to severe cognitive disturbances, such as delirium, during withdrawal (Hulse et al., 2005; Ritz et al., 2012). Acute substance use can also lead to severe structural damage, such as intracerebral or intraventricular hematoma associated with cocaine use, which would be detectable by CT or MRI and would profoundly complicate any subsequent withdrawal syndrome (Meza-Ruiz & Zúñiga-Escobar, 2023). In cases of severe intoxication leading to hypoxia or metabolic derangement, MRI can reveal patterns of brain damage, such as leukoencephalopathy, which may result in prolonged coma or persistent neurological deficits (Prajapati et al., 2024; Ciszowski & Mietka-Ciszowska, 2013). Therefore, in a patient presenting with altered mental status and suspected withdrawal from an unknown substance, neuroimaging is crucial to rule out acute structural pathologies that could mimic or complicate the withdrawal picture (Bullock & Teasdale, 1990; Sarkar et al., 2023).

**Functional Imaging (PET, fMRI, DTI):** Functional imaging studies have been instrumental in mapping the neural circuits of addiction and withdrawal. PET studies have demonstrated alterations in dopamine receptor availability and function in individuals addicted to stimulants, opioids, and alcohol (Volkow & Wolf, 1991; Koob et al., 2015). During withdrawal, these studies can reveal the hypodopaminergic state in reward circuits like the striatum, which correlates with symptoms of anhedonia and craving (George & Koob, 2017). fMRI studies that use cue-reactivity paradigms show that exposure to drug-related cues elicits robust activation in brain regions associated with reward, memory, and motivation—such as the amygdala, hippocampus, and prefrontal cortex—in addicted individuals, even during abstinence (Daley & Douaihy, 2019). This heightened reactivity of addiction-related circuits is a key neural correlate of craving and a predictor of relapse (Baker & Kalivas, 2005). Diffusion Tensor Imaging (DTI) allows for the examination of white matter microstructure, and studies have shown that chronic substance use can disrupt the integrity of white matter tracts connecting key brain regions, potentially contributing to impaired executive function and impulse control (Anghelescu et al., 2018). It is highly likely that withdrawal from any dependence-producing substance would be associated with a similar pattern of functional brain changes: hypoactivation of reward circuits, hyperactivation of stress and craving circuits, and impaired prefrontal cortical function (George & Koob, 2017).

### Neuroanatomical Correlates of Withdrawal Symptoms

The diverse symptomatology of withdrawal can be mapped onto the dysfunction of specific brain regions and networks.

*   **Anxiety, Irritability, and Dysphoria:** These core negative affective symptoms of withdrawal are linked to the hyperactivity of the extended amygdala and the brain's stress systems (George & Koob, 2017; Wand, 2008). This hyperactivity drives the unpleasant emotional state that motivates relapse (Jahan & Burgess, 2021).
*   **Cognitive Impairment:** Difficulties with attention, concentration, and executive function during withdrawal reflect the hypofrontality and disrupted connectivity of the prefrontal cortex (George & Koob, 2017; Ritz et al., 2012). Memory problems may be linked to dysfunction in the hippocampus and medial temporal lobes (Bernardín et al., 2014; Hulse et al., 2005).
*   **Psychosis:** Substance-induced and withdrawal-related psychosis, characterized by hallucinations and delusions, is thought to involve dysregulation of dopaminergic pathways in the mesolimbic system, similar to what is hypothesized in primary psychotic disorders like schizophrenia (Mauri, 2016; Boutros & Bowers, 1996; Snyder, 2019). The hippocampus may also be involved, particularly in cannabis-related psychosis (Kristensen, 1994).
*   **Seizures and Delirium:** The life-threatening generalized seizures and delirium seen in withdrawal from sedative-hypnotics are manifestations of widespread cortical hyperexcitability, resulting from the imbalance of GABAergic and glutamatergic systems (Thompson & Weber, 2021; Becker & Redmond, 2002). This represents a global failure of CNS inhibition (Yersin, 1999).
*   **Catatonia:** This neuropsychiatric syndrome of psychomotor disturbances can occur during withdrawal and has been linked to dysfunction in GABAergic and glutamatergic transmission, potentially involving circuits in the basal ganglia, cortex, and thalamus (Mohr, 2022; Zutshi et al., 2007; Yarlagadda et al., 2007).
*   **Craving:** The intense urge to use a substance during withdrawal is a complex phenomenon involving multiple brain regions. The insula is implicated in the conscious awareness of the urge, while the amygdala, hippocampus, and PFC are involved in processing cue-reactivity and driving the motivational state (George & Koob, 2017; Daley & Douaihy, 2019).

In summary, the withdrawal state is a syndrome of global brain dysfunction. While the initial pharmacological action of an unknown substance may be specific, the chronic adaptations and subsequent withdrawal syndrome involve a cascade of changes across interconnected neural networks that regulate reward, stress, emotion, and cognition (Roberts & Koob, 1997).

## Developmental Neurobiology

The impact of substance use and the nature of the subsequent withdrawal syndrome are profoundly influenced by the developmental stage of the individual, particularly during adolescence (McArdle & Angom, 2012; Schwartz, 1984). Adolescence is a critical period of neurodevelopment characterized by significant maturation of brain circuits, especially those involved in reward, motivation, and executive control (Winters & Ingwalson, 2022; Quartini et al., 2018). Exposure to psychoactive substances during this vulnerable period can disrupt normal brain development, leading to a higher risk of developing a substance use disorder and potentially more severe and complicated withdrawal syndromes later in life (McArdle & Angom, 2012; Winters & Ingwalson, 2022).

### Adolescence as a Critical Period of Vulnerability

The adolescent brain undergoes substantial remodeling, including synaptic pruning and myelination, particularly in the prefrontal cortex (PFC) (Quartini et al., 2018). The PFC, responsible for executive functions like impulse control and decision-making, matures later than the limbic reward systems, such as the nucleus accumbens (Winters & Ingwalson, 2022). This developmental mismatch creates a period where reward-seeking and risk-taking behaviors are heightened, while the capacity for top-down cognitive control is still developing (McArdle & Angom, 2012). This neurodevelopmental imbalance makes adolescents particularly susceptible to experimenting with psychoactive substances and progressing to compulsive use (Schwartz, 1984; Winters & Ingwalson, 2022).

Substance use during this period can interfere with these critical neurodevelopmental processes (Nešpor, 2004). For example, chronic cannabis use in adolescence has been associated with altered brain structure and function, and an increased risk of developing psychosis or schizophrenia, especially in genetically vulnerable individuals (Kristensen, 1994; Håkansson & Johansson, 2015; Sewell et al., 2010). Similarly, early and heavy alcohol use can impair brain development, leading to long-term cognitive deficits (Nešpor, 2004; Hulse et al., 2005). The introduction of any psychoactive substance, known or unknown, during this phase of heightened neuroplasticity can lead to more profound and lasting neuroadaptations, potentially resulting in a more severe dependence syndrome and a more intractable withdrawal state (Quartini et al., 2018; McArdle & Angom, 2012). The age of first use is a powerful predictor of the future development of a substance use disorder (Winters & Ingwalson, 2022).

### Impact on Withdrawal Phenomenology Across the Lifespan

The clinical presentation of withdrawal can also vary with age. While adolescents may exhibit the core neurobiological features of withdrawal, their presentation may be complicated by developmental factors, such as comorbid conduct problems, academic failure, and family conflict (Deas & Brown, 2006; Schwartz, 1984; Catheline, 2005). Psychiatric comorbidity is the rule rather than the exception in adolescents with SUDs, with high rates of depression, anxiety, and attention-deficit/hyperactivity disorder (ADHD) (Deas & Brown, 2006; Smith et al., 2002; Carlson & Pataki, 2016). These co-occurring disorders can obscure or mimic withdrawal symptoms, making diagnosis difficult (Deas & Brown, 2006). For example, irritability and mood swings could be symptoms of withdrawal, a primary mood disorder, or typical adolescent behavior (Gutton, 1980).

In older adults, withdrawal from an unknown substance presents a different set of challenges (Haaz & Gache, 2007; Johnson, 1989). Age-related physiological changes, such as decreased renal and hepatic function, can alter the pharmacokinetics of drugs, leading to accumulation and increased risk of toxicity (Kumagai & Iseki, 2012; Koch‐Weser et al., 1983). This can result in more prolonged and severe withdrawal syndromes (Haaz & Gache, 2007). Furthermore, older adults often have multiple medical comorbidities and are on multiple medications (polypharmacy), which increases the risk of drug interactions and can complicate the clinical picture of withdrawal (Jensen & Heck, 2012; Hulse, 2002).

The symptoms of withdrawal in the elderly are often atypical and may present as nonspecific complaints such as falls, confusion, self-neglect, or a general decline in function, a condition sometimes termed "failure to thrive" (Egbert, 1993; Palmer, 1990). A withdrawal-induced delirium can easily be mistaken for the progression of an underlying dementia (Hulse, 2002; Missler et al., 1999). Cognitive impairment, a common feature of aging, makes it difficult for older patients to provide a reliable history of substance use, further complicating diagnosis (Jensen & Heck, 2012). Given these factors, a high index of suspicion for substance withdrawal is necessary when an older adult presents with an acute change in mental or functional status (Haaz & Gache, 2007; Nassisi et al., 2006).

In summary, the neurobiology of withdrawal is not static but is dynamically influenced by the developmental stage of the brain and body. Exposure during the vulnerable period of adolescence can set the stage for more severe, long-term consequences (Winters & Ingwalson, 2022). In older adults, age-related physiological changes and comorbidities create a fragile state where withdrawal can manifest atypically and lead to severe medical complications (Hulse, 2002; Haaz & Gache, 2007). Therefore, a lifespan perspective is essential for understanding the biological basis and clinical presentation of withdrawal from any substance.

## Treatment Mechanisms

The management of Other (or Unknown) Substance Withdrawal is a significant clinical challenge, as the absence of a known substance precludes the use of specific, targeted antagonists or replacement therapies (Sarkar et al., 2023). However, a robust understanding of the general neurobiological principles underlying withdrawal syndromes allows for a rational, symptom-based approach to treatment (Thompson & Weber, 2021). The primary goals of management are to stabilize the patient, alleviate distressing and dangerous symptoms, prevent severe complications like seizures and delirium, and facilitate the transition to long-term treatment for the substance use disorder (Mahato et al., 2021; Kleber, 2007).

### Pharmacological Interventions: A Symptom-Based Approach

Pharmacotherapy for withdrawal from an unknown substance is largely supportive and directed at mitigating the consequences of CNS dysregulation (Thompson et al., 2021; Glance et al., 2015).

**Managing CNS Hyperexcitability:** The most immediate life-threatening risk in withdrawal from CNS depressants is severe hyperexcitability (Thompson & Weber, 2021). This state, driven by a GABA/glutamate imbalance, can lead to seizures and delirium tremens (Becker & Redmond, 2002; Yersin, 1999). The cornerstone of treatment for this type of withdrawal is the administration of a cross-tolerant GABA-agonist, most commonly a long-acting benzodiazepine such as diazepam or chlordiazepoxide (Thompson & Weber, 2021; Yersin, 1999). These agents substitute for the unknown substance at GABA-A receptors, restoring inhibitory tone and suppressing hyperexcitability (Nelson & Chouinard, 1999; Hollister, 1977). A symptom-triggered approach, where medication is given based on the severity of withdrawal signs (e.g., tremor, agitation, autonomic hyperactivity), is often preferred (Yersin, 1999). In a patient presenting with seizures, agitation, and autonomic instability, it is prudent to assume withdrawal from a sedative-hypnotic and initiate benzodiazepine treatment empirically while investigating other causes (Finer, 1971; Sarkar et al., 2023). Anticonvulsants like carbamazepine or valproic acid have also been used, as they can stabilize neuronal membranes and modulate GABAergic and glutamatergic systems (Sethi, 2001; Soler & Guasch, 2002).

**Managing Autonomic Hyperactivity:** The autonomic storm seen in opioid and alcohol withdrawal, characterized by tachycardia, hypertension, and diaphoresis, is driven by hyperactivity in noradrenergic systems, particularly in the locus coeruleus (Becker & Redmond, 2002; Rabinak & Nirenberg, 2010). Alpha-2 adrenergic agonists like clonidine can be used to suppress this sympathetic outflow, thereby alleviating many of the physical symptoms of withdrawal (Kleber, 2007; Thompson & Weber, 2021). While not a primary treatment for withdrawal, they can be a useful adjunct to manage autonomic instability. Beta-blockers may also be used to control tachycardia and hypertension, but must be used with caution (Karssemeijer et al., 2021).

**Managing Psychotic and Affective Symptoms:** Psychosis, depression, and anxiety are common during withdrawal from a variety of substances, including stimulants, cannabis, and alcohol (Pitchot et al., 2013; Thompson & Weber, 2021; Hughes et al., 1994). When psychotic symptoms like paranoia or hallucinations are prominent, short-term use of antipsychotic medications may be necessary (Garza-Treviño, 1988). Second-generation antipsychotics may be preferred due to a lower risk of extrapyramidal side effects (Battaglia et al., 2007). However, caution is required as some antipsychotics can lower the seizure threshold, which could be dangerous in a patient withdrawing from a sedative (Grover et al., 2022; Gamsızkan, 2018). For depressive and anxiety symptoms, supportive care is primary, as these symptoms often resolve as the acute withdrawal phase passes (Gorwood, 1999). If symptoms are severe or persist, treatment with antidepressants may be considered, though their onset of action is delayed (Daley & Douaihy, 2006). Trazodone has been suggested for its utility in managing insomnia and anxiety during withdrawal from alcohol and benzodiazepines (Funk, 2013).

**Opioid Agonist and Antagonist Therapy:** In cases where opioid withdrawal is strongly suspected based on the clinical presentation (e.g., mydriasis, rhinorrhea, piloerection, severe myalgias), opioid agonist therapy with methadone or buprenorphine is the treatment of choice (Thompson & Weber, 2021; Kleber, 2007). These agents occupy mu-opioid receptors, alleviating withdrawal symptoms and craving without producing the same intense euphoria as heroin (Noble & Roques, 2003; Kleber, 2007). The use of an opioid antagonist like naloxone would be diagnostic but could precipitate a severe, dangerous withdrawal syndrome and should generally be avoided unless treating an overdose (Sarkar et al., 2023; Kleber, 2007).

### Neuroplasticity, Compensatory Mechanisms, and Long-Term Treatment

The goal of detoxification is only the first step (Mahato et al., 2021). The neuroplastic changes underlying addiction persist long after acute withdrawal symptoms have subsided, leaving the individual vulnerable to craving and relapse for months or years (George & Koob, 2017; Baker & Kalivas, 2005). Effective treatment must therefore address these long-term neurobiological vulnerabilities.

Medication-assisted treatment (MAT) aims to stabilize brain chemistry and reduce the drive to use illicit substances (Daley & Douaihy, 2019; Rao, 2008). For opioid use disorder, long-term maintenance with methadone or buprenorphine is highly effective at preventing relapse (Kleber, 2007). For alcohol use disorder, medications like naltrexone (an opioid antagonist that reduces the rewarding effects of alcohol) and acamprosate (which helps normalize glutamate/GABA balance) can support abstinence (Rao, 2008; Dongier, 2003). While these medications are specific, the principle of using pharmacotherapy to modulate the underlying neurocircuitry of addiction is a key strategy (Daley & Douaihy, 2019).

Psychosocial interventions, such as cognitive-behavioral therapy (CBT) and motivational enhancement therapy, are essential components of treatment (Rao, 2008; Mahato et al., 2021). These therapies work by targeting the cognitive and behavioral aspects of addiction that are driven by the underlying neurobiological changes. CBT helps patients identify and change maladaptive thought patterns and behaviors associated with drug use, effectively helping to retrain the executive control circuits in the PFC (Rao, 2008). Motivational interventions help resolve ambivalence and strengthen the motivation for change, targeting the motivational circuits disrupted by addiction (Rao, 2008; Galanter, 2014). By providing skills to manage cravings and cope with stressors, these therapies help individuals counteract the powerful neurobiological drive to relapse (Daley & Douaihy, 2019). Ultimately, successful recovery involves the brain's own neuroplastic capacity to relearn healthy behaviors and restore a degree of normal function to the circuits disrupted by chronic substance use (George & Koob, 2017).

## Future Directions

The study of Other (or Unknown) Substance Withdrawal is, by its very nature, a frontier in addiction medicine and neuroscience. The landscape of substance use is constantly evolving, with the continuous emergence of new psychoactive substances (NPS), synthetic cannabinoids, and novel synthetic opioids, often consumed in unpredictable combinations (Wojtyła-Buciora et al., 2023; Coman et al., 2019). This dynamic environment presents profound challenges for clinicians, toxicologists, and researchers, highlighting several critical areas for future investigation.

A primary challenge is the rapid identification of novel substances in clinical settings. Current urine toxicology screens are often unable to detect NPS, leading to diagnostic uncertainty (Sarkar et al., 2023; Sweet et al., 2017). Future research must focus on developing rapid, broad-spectrum toxicological assays, potentially utilizing advanced mass spectrometry techniques, that can be deployed in emergency departments to identify the causative agent(s) in cases of acute intoxication and withdrawal (Anghelescu et al., 2018). This would move the field from a purely syndromic approach to a more precise, substance-specific diagnosis and management strategy.

Furthermore, a deeper understanding of the neurobiology of these novel substances is urgently needed. While we can extrapolate from known drug classes, NPS often have unique pharmacological profiles, acting as potent agonists or antagonists at multiple receptor systems simultaneously (Wojtyła-Buciora et al., 2023; López‐Arnau et al., 2022). Preclinical research using animal models is essential to characterize the mechanisms of action, addiction potential, and withdrawal phenomenology of these new compounds. This research should investigate their effects on key neurotransmitter systems (dopamine, serotonin, glutamate, GABA) and their impact on the neural circuits of reward, stress, and executive function (Scuvée‐Moreau, 2013; George & Koob, 2017).

Neuroimaging represents a powerful tool for bridging the gap between preclinical models and human psychopathology. Longitudinal neuroimaging studies could track individuals who use NPS to identify structural and functional brain changes associated with chronic use and withdrawal. Techniques like fMRI and PET could elucidate how these new drugs impact reward circuitry, prefrontal cortex function, and neural connectivity, providing objective biomarkers of withdrawal severity and relapse risk (Volkow & Wolf, 1991). This could help differentiate substance-induced brain changes from pre-existing vulnerabilities or comorbid psychiatric conditions (Koob et al., 2015).

The genetic and epigenetic basis of vulnerability to NPS addiction and withdrawal is another vital area of inquiry. Genome-wide association studies (GWAS) could identify genetic variants that increase the risk for developing dependence on these novel substances, analogous to the work done for alcohol and nicotine (Blum & Trachtenberg, 1988). Research into epigenetic modifications could reveal how the use of these substances leaves long-lasting marks on gene expression, contributing to the chronicity of the disorder and providing potential targets for future therapeutic interventions (Amoah et al., 2022).

From a clinical perspective, there is a pressing need for controlled trials to establish evidence-based treatments for withdrawal from NPS. While symptom-based management is the current standard of care, it is largely based on experience with older drugs (Thompson & Weber, 2021). We need to investigate whether existing detoxification protocols are effective and safe for withdrawal from synthetic cannabinoids or cathinones, and explore novel pharmacological approaches. For example, understanding the receptor binding profiles of new synthetic opioids might suggest which maintenance therapies (e.g., methadone, buprenorphine) are most effective (Kleber, 2007). Similarly, exploring agents that modulate the glutamatergic or endocannabinoid systems could offer new avenues for treating withdrawal from synthetic cannabinoids or stimulants (Connor et al., 2021).

Finally, the heterogeneity of withdrawal syndromes, even from a single unknown substance, underscores the need for a personalized medicine approach. Future research should aim to identify biological subtypes of withdrawal based on clinical phenomenology, genetic markers, and neuroimaging profiles. This could lead to the development of tailored treatment algorithms that match specific interventions to the patient's underlying neurobiological state (George & Koob, 2017). For instance, a patient with a withdrawal profile dominated by negative affect and anhedonia might benefit more from an intervention targeting stress and reward circuits, whereas a patient with severe cognitive impairment might benefit from cognitive remediation therapies targeting prefrontal function (Bernardín et al., 2014). Acknowledging and studying this heterogeneity, rather than treating withdrawal as a monolithic entity, will be key to improving outcomes for this complex and challenging patient population.

## Conclusion

Other (or Unknown) Substance Withdrawal is a complex and often severe clinical syndrome that represents a state of acute, profound neurobiological dysregulation. While the specific inciting agent may be unidentified, the underlying pathophysiology is rooted in the fundamental principles of addiction neuroscience. Chronic exposure to any dependence-producing substance induces a series of neuroadaptive changes in the brain's reward, stress, and executive control circuits, creating an allostatic state that is dependent on the drug's continued presence (George & Koob, 2017; Koob et al., 2015). The abrupt cessation of the substance unmasks these adaptations, resulting in a withdrawal syndrome characterized by symptoms that are typically opposite to the drug's acute effects and reflect a dramatic imbalance in key neurotransmitter systems, including dopamine, GABA, glutamate, and serotonin (Thompson & Weber, 2021; Becker & Redmond, 2002).

The clinical presentation is remarkably heterogeneous, capable of mimicking a wide range of primary psychiatric and medical disorders, from anxiety and mood disorders to delirium and psychosis (Chouinard & Chouinard, 2015; Mihanović et al., 2009; Sarkar et al., 2023). This heterogeneity is shaped by the unknown substance's specific pharmacology, the duration and intensity of use, individual genetic vulnerabilities, and the developmental stage of the patient (Winters & Ingwalson, 2022; Hulse, 2002). The diagnostic process is therefore one of careful clinical assessment, high suspicion, and the exclusion of other organic etiologies, as withdrawal from certain substances can be life-threatening (Thompson et al., 2021).

Management, in the absence of a known substance, must be guided by a symptom-based approach targeting the underlying neurobiological state. CNS hyperexcitability is managed by restoring GABAergic tone with benzodiazepines; autonomic hyperactivity is controlled with adrenergic agents; and severe affective or psychotic symptoms may require short-term adjunctive psychotropics (Yersin, 1999; Kleber, 2007; Battaglia et al., 2007). However, detoxification is merely the first step. The enduring neuroplastic changes of addiction necessitate long-term, integrated treatment that combines pharmacotherapy and psychosocial interventions to manage cravings, prevent relapse, and support the brain's capacity for recovery (Mahato et al., 2021; Rao, 2008).

The ever-shifting landscape of new psychoactive substances ensures that Other (or Unknown) Substance Withdrawal will remain a persistent challenge. Future progress depends on the development of rapid toxicological screening, dedicated neurobiological research into novel drugs, and clinical trials to establish evidence-based treatment protocols. By continuing to unravel the fundamental biological and neurological mechanisms of addiction and withdrawal, we can refine our approach to this complex syndrome, moving toward more precise diagnostics and personalized therapeutic strategies that can mitigate harm and foster lasting recovery.

## References

1. Abascal, R. R., Sendin, P. M., & Juan, M. E. A. (2008). Adicciones en Anestesiología. Revista de la Escuela de Medicina Legal. https://doi.org/10.5209/rev_reml.2008.n9.50286
2. Abdallah, S. J., Poenaru, S., Corrales‐Medina, V., & Cowan, J. (2021). COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Therapeutic Advances in Infectious Disease. https://doi.org/10.1177/20499361211009385
3. AbdulRahman, I., Yaqoob, Ú., & Bhatti, T. A. (2018). Sleep Disorders Caused by Depression. Clinical Depression. https://doi.org/10.4172/2572-0791.1000131
4. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
5. Adicaram, D. R. S., Wijayamunige, E. S., & Arambepola, S. C. A. (2021). Vampires! Do they exist? A case of clinical vampirism. Sri Lanka Journal of Psychiatry. https://doi.org/10.4038/sljpsyc.v12i2.8299
6. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
7. Aghababaeian, H., & Ahvazi, L. A. (2018). Isn’t it Time to Use Opioid Drugs in Emergency Medical Services?. DOAJ (DOAJ: Directory of Open Access Journals).
8. Aichmüller, C., & Soyka, M. (2015). Müdigkeit bei Suchterkrankungen. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. https://doi.org/10.4414/smf.2015.02258
9. Ajiboye, P., & Yusuf, A. D. (2013). Scientific Letter: Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): A report of two cases. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v16i2.11
10. Akan, M., & Cumurcu, H. B. (2022). Cocaine use and related pathologies. Current Addiction Research. https://doi.org/10.5455/car.105-1632808119
11. Alexander, R., & Bhaumik, S. (2015). Personality Disorders. https://doi.org/10.1002/9781118897164.ch19
12. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
13. Alghamdi, B., Zrari, M., Elahi, A. M. N., Alwagdani, M., Alghamdi, E. A. S., Moafa, H., Miran, S., Alamoudi, S., Alshahrani, K., Binnwejim, M., & jaafari, M. A. (2018). Substance abuse and its psychiatric effect on adolescence. International Journal of Community Medicine and Public Health. https://doi.org/10.18203/2394-6040.ijcmph20182450
14. Alhashimi, R., Thoota, S., Ashok, T., Palyam, V., Azam, A. T., Odeyinka, O., & Sange, I. (2022). Comorbidity of Epilepsy and Depression: Associated Pathophysiology and Management. Cureus. https://doi.org/10.7759/cureus.21527
15. Ali, M., Malathesh, B. C., Chatterjee, S. S., Das, S., & Prasad, S. (2022). Mania/Hypomania induced by quetiapine: A case report and review of literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100093
16. Allgulander, C., & Baldwin, D. S. (2013). Pharmacotherapy of Generalized Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351955
17. Alqallaf, M. (2021). Toxicological Aspect of Fatal Methamphetamine. Chemical & Pharmaceutical Research. https://doi.org/10.33425/2689-1050.1016
18. Altunoz, U., Menstell, J., & Ziegenbein, M. (2022). When depression envelops frontotemporal dementia: The differential diagnostic frame through a case report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1664
19. Alvarez, J. A., Sánchez, E., & Almarcha, L. M. (2025). The craziness in losing weight. A systematic review and case report of sibutramine’s psychosis. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.2203
20. Alvarez, M. R., García, R. G., & Silva, F. A. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas. Acta neurológica colombiana.
21. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
22. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
23. Amron, S. B., Kandasami, G., Lee, C., Guo, S. L., & Tan, H. (2025). Making sense of ICD-11 diagnostic criteria of compulsive sexual behavioural disorder. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024266
24. Anani, S., Goldhaber, G., Wasserstrum, Y., Dagan, A., & Segal, G. (2018). The ‘SILENT Alarm’: When History Taking Reveals a Potentially Fatal Toxicity. European Journal of Case Reports in Internal Medicine. https://doi.org/10.12890/2018_000843
25. Anderson, T., Heitger, M., & Macleod, A. D. (2006). Concussion and mild head injury. Practical Neurology. https://doi.org/10.1136/jnnp.2006.106583
26. Andresen, M., & Andresen-Vasquez, M. (2016). A new instrument for assessing the experience of dying and death in the intensive care units from the perspective of relatives. Journal of Thoracic Disease. https://doi.org/10.21037/jtd.2016.06.07
27. Andréasson, S., Berglund, M., Franck, J., Fridell, M., Håkansson, I., Johansson, B., Lindgren, A., Lindgren, B., Nicklasson, L., Rydberg, U., Salaspuro, M., Thelander, S., & Öjehagen, A. (2001). Behandling av alkohol- och narkotikaproblem: En evidensbaserad kunskapssammanställning.
28. Anghel, L., Boev, M., Stănescu, C., Caramfil, S. M., Luca, L., Mușat, C. L., & Ciubară, A. (2023). Depression in the Diabetic Patient. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/14.4/526
29. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
30. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). ORAL PRESENTATION – ABSTRACTS. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s.1
31. Anghelescu, A., Saglam, A.-O., Stoica, S. I., & Onose, G. (2022). Rehabilitation of severe neurological complications post SARS-CoV-2 infection. Balneo and PRM Research Journal. https://doi.org/10.12680/balneo.2022.491
32. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
33. Anisman, H. (2015). Addictions and Forbidden Fruits. https://doi.org/10.1002/9781118850350.ch16
34. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
35. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
36. Antoniuk, S. A. (2013). [Non-epileptic disorders in infancy and adolescence].. PubMed.
37. Arbuck, D. M. (2022). Neurotransmitter-based diagnosis and treatment: A hypothesis (Part 2). Current psychiatry. https://doi.org/10.12788/cp.0253
38. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
39. Armstrong, E. J. (2021). The Forensic Toxicological Aspects of Deaths Due to Drowning and Bodies Recovered from Fluid Environments. CRC Press eBooks. https://doi.org/10.4324/9780367332297-10
40. Arnáez, S. (2019). Vulnerabilidad cognitiva a la hipocondría: intrusiones, valoraciones y creencias disfuncionales/ cognitive vulnerability to hypochondriasis: intrusions, appraisals and dysfunctional beliefs.
41. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
42. Attia, E., & Kostro, K. (2015). Pica. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp374
43. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
44. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
45. Aveyard, P., & Raw, M. (2012). Improving smoking cessation approaches at the individual level. Tobacco Control. https://doi.org/10.1136/tobaccocontrol-2011-050348
46. Ayoob, A., & Janakiram, C. (2021). Let's Focus on Frailty. Journal of Indian Association of Public Health Dentistry. https://doi.org/10.4103/jiaphd.jiaphd_93_21
47. Babor, T. F., Hernández–Ávila, C. A., & Ungemack, J. A. (2015). Substance‐Related Disorders: Alcohol‐Related Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch72
48. Bahro, M., Missler, G., & Strnad, J. (1999). [Diagnosis and therapy of alcohol-withdrawal symptoms in the elderly: a case report].. PubMed.
49. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
50. Baker, D. L., & Kalivas, P. W. (2005). Sensitization and Relapse. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-852-6_15
51. Baldaçara, L., Ramos, A., & Castaldelli-Maia, J. M. (2023). Managing drug-induced psychosis. International Review of Psychiatry. https://doi.org/10.1080/09540261.2023.2261544
52. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
53. Balis, G. U. (2018). Psychoactive Substance Use Disorders. Routledge eBooks. https://doi.org/10.4324/9781315825908-16
54. Balis, G. U. (2018). Syndromes Similar to Functional Disorders. Routledge eBooks. https://doi.org/10.4324/9781315825908-13
55. Barnes, T. R. E., & Paton, C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. https://doi.org/10.1136/bmj.d3371
56. Barnhill, J. W., Loewenstein, R. J., Simeon, D., & Lewis‐Fernández, R. (2023). Dissociative Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615375295.jb08
57. Barolin, G. S. (1998). Rehabilitation hospitalism. International Journal of Rehabilitation Research. https://doi.org/10.1097/00004356-199806000-00008
58. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
59. Barrio, A. G. D. (2018). Intervención Psicoterapéutica Integrada y Transdiagnóstica en los Trastornos de la Conducta Alimentaria. Revista de Psicoterapia. https://doi.org/10.33898/rdp.v29i110.248
60. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
61. Bartova, L. (2025). Typical clinical manifestations of anxiety and depression in patients with medical illness and general notions about their treatment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.174
62. Bassetti, C. L. (2007). Differential diagnosis and management of non-psychiatric acute confusional states. Schweizer Archiv für Neurologie und Psychiatrie. https://doi.org/10.4414/sanp.2007.01901
63. Battaglia, J., Robinson, D. G., & Citrome, L. (2007). The Treatment of Acute Agitation in Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026146
64. Baud, P. (2011). [Risk factors and psychosocial disability of treatment-resistant depression].. PubMed.
65. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
66. Becker, M. A., Weinberger, T. E., & Ocker, L. J. (2022). Mood Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003099062-21
67. Becker, S. P., & Barkley, R. A. (2018). Sluggish cognitive tempo. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198739258.003.0015
68. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
69. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
70. Benjaminsen, S. (2013). Delirium blandt ældre indlagte patienter er hyppig og har dårlig prognose. Research Portal Denmark.
71. Berg, J., & Grimeland, J. (2012). Obsessive-compulsive disorder in disguise—Case report. Open Journal of Psychiatry. https://doi.org/10.4236/ojpsych.2012.23026
72. Berg, J., Liempt, S. V., & Verwijk, E. (2019). Differentiële diagnostiek en behandeling van insomnie bij ouderen.
73. Bermúdez, C. M., & Barrientos, M. P. S. (2011). Manejo Integral de un paciente con secuelas neuropsiquiátricas por consumo crónico de alcohol. REVISTA MÉDICAS UIS.
74. Bernardin, F., Maheut-Bosser, A., & Paillé, F. (2014). [Cognitive impairment of alcohol-dependent subjects].. PubMed.
75. Bewley, T. H. (1975). The illicit drug scene.. BMJ. https://doi.org/10.1136/bmj.2.5966.318
76. Bhorania, S., Swati, P., & Justin, P. (2025). COGNITION DUE TO LESS SLEEP DURATION: AFFECTED OR NOT AFFECTED. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/9502595
77. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
78. Bismuth, C., Bellec, L., Dally, S., & Lagier, G. (1980). [Benzodiazepine physical dependence. 6 cases (author's transl)].. PubMed.
79. Biswas, S., Raju, N. S. G., & Patel, K. R. (2015). Should Non-psychiatrists Be Trained to Recognize and Treat Co-morbid Depression?. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31023-3
80. Blum, K., & Trachtenberg, M. C. (1988). Alcoholism: Scientific Basis of a Neuropsychogenetic Disease. International Journal of the Addictions. https://doi.org/10.3109/10826088809058839
81. Boggs, C. L., Ripple, M., Ali, Z., Brassell, M., Levine, B., Jufer‐Phipps, R., Doyon, S., & Fowler, D. R. (2013). Anaphylaxis After the Injection of Buprenorphine. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12161
82. Bonnet, U., Specka, M., Abedi, R. H., Wiltfang, J., & Scherbaum, N. (2009). Severe Protracted Alcohol Withdrawal Syndrome: Prevalence and Pharmacological Treatment at an Inpatient Detoxification Unit – A Naturalistic Study. Pharmacopsychiatry. https://doi.org/10.1055/s-0028-1103292
83. Borovac, A. (2018). Zdravstvena njega bolesnika - ovisnika o psihoaktivnim tvarima.
84. Bosch, W. V. D., & Weel‐Baumgarten, E. V. (2003). [Depression: longer-lasting episode not an automatic indication for referral].. PubMed.
85. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
86. Bourin, M., David, D. J., & Dhonnchadha, B. À. N. (2002). Sedation: a non-specific phenomenon -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
87. Bouritius, E. M., Neven, A. K., & Blom, J. D. (2015). [Alcohol hallucinosis].. PubMed.
88. Boutros, N. N., & Bowers, M. B. (1996). Chronic substance-induced psychotic disorders: state of the literature. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.8.3.262
89. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
90. Brandish, E. K., & Baldwin, D. S. (2012). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2012.08.017
91. Breggin, P. R. (2012). Psychiatric Drug Withdrawal. https://doi.org/10.1891/9780826108449
92. Brodrick, J. E., & Mitchell, B. G. (2015). Hallucinogen Persisting Perception Disorder and Risk of Suicide. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014566314
93. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
94. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
95. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
96. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
97. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
98. Bukhari, S. N. A. (2022). Consequences of Antipsychotic Medications on Mental Health. Current Drug Safety. https://doi.org/10.2174/1574886317666220216101106
99. Bullock, R., & Teasdale, G. (1990). ABC of major trauma. Head injuries--II.. BMJ. https://doi.org/10.1136/bmj.300.6739.1576
100. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Supplementary Material for: Post-Stroke Apathy: An Exploratory Longitudinal Study. Figshare. https://doi.org/10.6084/m9.figshare.5124829
101. Campana, R. (2017). The Basics of Addiction. MOJ Addiction Medicine & Therapy. https://doi.org/10.15406/mojamt.2017.03.00046
102. Cano‐Vindel, A., Miguel-Tobal, J. J., González, H. M., & Díez, I. I. (1994). El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología.
103. Caradoc-Davies, G. (1988). Feigned Alcohol Abuse. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.152.3.418
104. Caraiane, A., Szalontay, A. S., Macovei, L. A., Romila, A., Indrei, L. L., Decusară, M., & Tarc, T. (2018). Oral-Facial Manifestations Caused by the Use of Psychotropic Medication in Psychiatric Patients. Revista de Chimie. https://doi.org/10.37358/rc.18.6.6374
105. Carlson, G. A., & Pataki, C. (2016). Disruptive Mood Dysregulation Disorder Among Children and Adolescents. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20150039
106. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
107. Casanova, Y. C., Torres, M. N., Ramírez, M. D. L., Ferrer, A. B., Calvo, R. N., & Ramos, I. J. (2021). Plan de cuidados de enfermería para paciente con deterioro de la movilidad.. Revista Sanitaria de Investigación.
108. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
109. Catheline, N. (2005). [Academic problems and school failure in adolescence].. PubMed.
110. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
111. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
112. Charante, E. P. M. V., Richard, E., & Perry, M. (2022). [Forgetfulness].. PubMed.
113. Charlesworth, J., Ghosn, O., Hussain, N., Mahmoud, R., Goncalves, V., & Godbole, M. (2023). A case report of an unusual presentation of a patient with recurrent idiopathic catatonia. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100111
114. Charmaz, K. (1983). Loss of self: a fundamental form of suffering in the chronically ill. Sociology of Health & Illness. https://doi.org/10.1111/1467-9566.ep10491512
115. Charmaz, K. (2007). Chronic Illness and Disability. The Blackwell Encyclopedia of Sociology. https://doi.org/10.1002/9781405165518.wbeosc035
116. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
117. Chaudhry, H., Arshad, N., Niaz, S., Cheema, F., Iqbal, M., & Mufti, K. (2005). Fifteen-year follow-up of conversion disorder. International Psychiatry. https://doi.org/10.1192/s1749367600007517
118. Chee, K. T., Sim, K., Lee, T. S., & Ng, B. Y. (2010). Making Sense of Kleptomania: Clinical Considerations. Proceedings of Singapore Healthcare. https://doi.org/10.1177/201010581001900403
119. Chesney, E., Reilly, T. J., Scott, F., Slimani, I., Sarma, A. V. S., Kornblum, D., Oliver, D., & McGuire, P. (2024). Psychosis associated with cannabis withdrawal: systematic review and case series. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.2024.175
120. Chicoș, O., Perri, D., Capriș, L., Iliescu, A. I. B., & Kantor, C. (2019). Social-Cultural Influences and Personality Disorders Favoring Drug Consumption. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s1/3
121. Choo, K.-Q., Wl, L., How, C., & Ng, B. (2015). Hoarding in Singapore. Singapore Medical Journal. https://doi.org/10.11622/smedj.2015131
122. Chouinard, G., & Chouinard, V. (2015). New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000371865
123. Chuen, L. H. (2022). Traditional Chinese Medicine Offers Help to Marijuana Users Determined to Withdraw Report of Two Typical Cases. Journal of Drugs Addiction & Therapeutics. https://doi.org/10.47363/jdat/2022(3)121
124. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
125. Cid, A. S. (1990). El deterioro neuropsicologico y neurofisiologico en la esquizofrenia.
126. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Rare consciousness disturbances in toxicological practice: akinetic mutism, somnambulism, locked-in syndrome, and psychogenic coma].. PubMed.
127. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
128. Clark, M., & McKinlay, J. (2009). Coma, Confusion, and Agitation in Intensive Care. Competency-based critical care. https://doi.org/10.1007/978-1-84882-070-8_11
129. Clayton, A., Dennerstein, L., Pyke, R. E., & Sand, M. (2010). Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women. Women s Health. https://doi.org/10.2217/whe.10.54
130. Cleeland, C. S., & Mendoza, T. R. (2010). Symptom measurement by patient report. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511780868.028
131. Cohen, J. A., Mowchun, J. J., Lawson, V. H., & Robbins, N. M. (2016). A 19-Year-Old Male with Stiffness and Weakness After Waking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190491901.003.0026
132. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
133. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Managementul tratamentului tulburărilor cauzate de consumul de substanţe psihoactive. Psihiatru ro.
134. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Treatment management of psychoactive substance use disorders. Psihiatru ro. https://doi.org/10.26416/psih.59.4.2019.2604
135. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
136. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
137. Correia‐Melo, F. S., Silva, S. S., Araújo-de-Freitas, L., & Quarantini, L. C. (2017). S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Brazilian Journal of Psychiatry. https://doi.org/10.1590/1516-4446-2016-2070
138. Corruble, E., Warot, D., & Soubrie, C. (2003). Insomnia linked to medications. SLEEP. https://doi.org/10.1007/978-1-4615-0217-3_20
139. Cortés, V. A. L. (2018). Características neuropsicológicas de pacientes con enfermedad de Parkinson sin demencia. https://doi.org/10.14201/gredos.139596
140. Cottencin, O., Danel, T., Goudemand, M., Thomas, P., & Consoli, S. M. (2009). Catatonia recognition and treatment.. PubMed.
141. Cotter, T. G., & Beresford, T. P. (2022). Treatment of Mental Health in Patients With Chronic Liver Disease. Clinical Liver Disease. https://doi.org/10.1002/cld.1200
142. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
143. Cowan, A. (2012). Psychotic Disorders. https://doi.org/10.1002/9781119945925.ch9
144. Crișan, C. A. (2018). Lack of Insight in Bipolar Disorder: The Impact on Treatment Adherence, Adverse Clinical Outcomes and Quality of Life. InTech eBooks. https://doi.org/10.5772/intechopen.76286
145. Crome, I., & Ghodse, H. (2007). Drug misuse in medical patients. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543975.010
146. Csernus, I., Gaszner, P., Fülöp, B., & Gaszner, G. (2004). [Schizoid psychosis during cannabis intake (case report)].. PubMed.
147. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
148. Dadkhah, B., Valizadeh, S., Mohammadi, E., & Hassankhani, H. (2013). Psychosocial adjustment to lower-limb amputation: A review article.
149. Dakwar, E., Nunes, E. V., Bisaga, A., Carpenter, K. C., Mariani, J. P., Sullivan, M. A., Raby, W. N., & Levin, F. R. (2011). A Comparison of Independent Depression and Substance-Induced Depression in Cannabis-, Cocaine-, and Opioid-Dependent Treatment Seekers. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2011.00148.x
150. Daley, D. C., & Douaihy, A. (2006). Medications in Dual Recovery. https://doi.org/10.1093/oso/9780195311297.003.0006
151. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
152. Daley, D. C., & Douaihy, A. (2006). Understanding Mood Disorders: Depression and Bipolar Illness. https://doi.org/10.1093/oso/9780195311297.003.0003
153. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
154. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
155. Daley, D. C., & Douaihy, A. (2019). Psychiatric Illness Co-occurring with a Substance Use Problem. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0008
156. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
157. Daley, D. C., & Douaihy, A. (2019). Understanding Substance Use Problems. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0002
158. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
159. Darke, S., Degenhardt, L., & Mattick, R. P. (2006). Mortality and drug overdose. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543692.004
160. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
161. Day, E., & Morris, J. P. (2021). Historical and Conceptual Approaches to Addiction. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623199.002
162. Deas, D., & Brown, E. S. (2006). Adolescent Substance Abuse and Psychiatric Comorbidities. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.0706e02
163. Deering, C. G. (2013). Schizophrenia. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp471
164. Delcea, C. (2019). Dyspareunia in men. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.120
165. Delcea, C. (2019). Orgasmic disorder in women. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.122
166. Delcea, C. (2019). Sexual deviances. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.119
167. Delgado, Y. O., Reyes, A. C., & Imas, Y. A. (2012). Trastorno por estrés agudo: Presentación de un caso. Cuadernos de Medicina Forense. https://doi.org/10.4321/s1135-76062012000100004
168. Delgado‐Losada, M. L., Aizcorbe, J. R. R., & Guinea, S. F. (2001). Aspectos de la Neuropsicología Forense en el envejecimiento y en las demencias. Revista de Neurología. https://doi.org/10.33588/rn.3208.2000187
169. Delroisse, S., Clumeck, N., Gozlan, S., Polain, M. L., Massart, A., Mesters, P., & Pitchot, W. (2017). [Professional fatigue syndrome (burnout). Part 1 : identification by the general practitioner].. PubMed.
170. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
171. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
172. Dias, I. M., Maia, I. D., Mello, L. M. R. D., Leite, I. C. G., & Leite, F. P. P. (2014). Evaluation of correlation among sleep bruxism and depression levels, chronic pain and nonspecific physical symptoms according to axis II of the Research Diagnostic Criteria/Temporomandibular disorders. RSBO Revista Sul-Brasileira de Odontologia.
173. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
174. Dille, J. R. (1991). Chronic fatigue syndrome.. PubMed.
175. DiLossi, J., & Harrison, M. (2023). Understanding Eating Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781009186865.004
176. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
177. Dobrin, I., Chiriță, R., Straulea, A. O., Ciobîcă, A., & Dobrin, R. (2010). Some comorbidities of benzodiazepine addicted patients.
178. Donghi, A., Maidana, M., Vázquez, L. G., & Rodríguez, R. O. (2011). DIAGNÓSTICO DIFERENCIAL (NEUROSIS-PSICOSIS) DEL MODO DE TRATAMIENTO DEL DOLOR EN CONSUMIDORES DE PASTA BASE DE COCAÍNA (PACO). III Congreso Internacional de Investigación y Práctica Profesional en Psicología XVIII Jornadas de Investigación Séptimo Encuentro de Investigadores en Psicología del MERCOSUR.
179. Dongier, M. (2003). What treatment options exist for alcohol abuse?. Journal of Psychiatry and Neuroscience. https://doi.org/10.1139/jpn.0307
180. Douglas, K. S. (2015). Addiction and Violence Risk. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp432
181. Dreifuss, F. E. (1995). Prevention as It Pertains to Epilepsy. Archives of Neurology. https://doi.org/10.1001/archneur.1995.00540280045017
182. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
183. Dukku, A. M. (2021). DRUG AND SUBSTANCE ABUSE AMONG YOUTH IN NIGERIA: TYPES, CAUSES AND IMPLICATIONS ON SOCIO-ECONOMIC DEVELOPMENT. INTERNATIONAL JOURNAL OF MANAGEMENT, SOCIAL SCIENCES, PEACE AND CONFLICT STUDIES.
184. Duma, S., & Fung, V. S. (2019). Drug-induced movement disorders. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.014
185. Dunnigan, M., Czapla, K., Henderson, J. B., & Pelosi, A. J. (1999). The Fluid Retention Syndrome: Recognition, Risk Factors and Management. The Journal of the British Menopause Society. https://doi.org/10.1177/136218079900500206
186. Díez‐Tejedor, E., Tejada, J. H., & Frank, A. (1989). [Neurologic complications caused by use of cocaine, amphetamines and sympathomimetics].. PubMed.
187. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
188. D’Souza, R. S., & Hooten, W. M. (2019). Somatic Syndrome Disorders.
189. Edinoff, A. N., Sauce, E., Ochoa, C., Cross, J., Cogburn, M., Cornett, E. M., Kaye, A. M., Pham, A., & Kaye, A. D. (2021). Clozapine and Constipation: A Review of Clinical Considerations and Treatment Options. Psychiatry International. https://doi.org/10.3390/psychiatryint2030026
190. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
191. Egbert, A. M. (1993). 'The dwindles'. Failure to thrive in older patients.. PubMed.
192. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
193. Elikowski, W., Małek‐Elikowska, M., Fertała, N., & Zawodna-Marszałek, M. (2021). Amiodarone-induced musical hallucinations.. PubMed.
194. Emilien, G., Dinan, T. G., Lepola, U., & Durlach, C. (2002). Generalised anxiety disorder. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-8157-9_3
195. Ereshefsky, L., Tran-Johnson, T., & Watanabe, M. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.. PubMed.
196. Escayola, E. N., Caballero, J. M. M.-Q., & Valencia, B. C. (2014). Valoración médico forense de muerte en custodia por delirium agitado. A propósito de un caso.
197. Escobar, J. I., & Canino, G. (1989). Unexplained Physical Complaints. The British Journal of Psychiatry. https://doi.org/10.1192/s000712500029572x
198. Escobar, M. G. T. (2021). Salud mental y porte de armas en personas que laboran para el Estado como agentes de seguridad. Sapientia. https://doi.org/10.54138/27107566.31
199. Espay, A. J., Chaná, P., González-Usigli, H., & LaFaver, K. (2015). Psychostimulants and movement disorders.
200. Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2006). Trastorno perceptivo persistente por alucinógenos después del consumo de psilocibina: un estudio clínico. European psychiatry (Ed Española). https://doi.org/10.1017/s1134066500003738
201. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
202. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
203. Evren, C., & Dalbudak, E. (2009). Relationship of Personality Trait Impulsivity with Clinical Variables in Male Alcohol-Dependent Inpatients. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
204. Falk, A., Joseph, R., Smith, S., & Wilk, A. (2023). Mood and Anxiety Disorders: Major Depressive Disorder.. PubMed.
205. Farooq, N. S. M. U., Alex, A., & Matthews, R. (2016). Opioid Medications: Psychiatric Diagnosis. Journal of Addiction Research & Therapy.
206. Faulkner, G., Gorczynski, P., & Arbour‐Nicitopoulos, K. P. (2015). Exercise as an Adjunct Treatment for Schizophrenia. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch38
207. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
208. Fawcett, J. (2021). Psychopharmacotherapy and Psychotherapy: Treating Target Symptoms and Learning. Routledge eBooks. https://doi.org/10.4324/9780203779118-3
209. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
210. Feder, H. M., & Wormser, G. P. (2021). Studying College Students for the Development of Infectious Mononucleosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab075
211. Feighner, J. P., & Boyer, W. F. (1989). Serotonin-IA Anxiolytics: An Overview. Psychopathology. https://doi.org/10.1159/000284623
212. Feltz, C. V. D., & Houdenhove, B. V. (2014). [DSM-5: from 'somatoform disorders' to 'somatic symptom and related disorders'].. PubMed.
213. Fernandez, H. H., Gálvez-Jiménez, N., & Hanson, M. R. (2012). Use of chemodenervation in dystonic conditions. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.79.s2a.05
214. Fernández, A. A., Martín, Á. P., Martínez, M. I., Bustillo, M. A., Hernández, F. B., Labrado, J. D. L. C., Peñas, R. D.-D., Rivas, E. G., Delgado, C. P., Redondo, J. R., & Giménez, J. R. R. (2009). Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. https://doi.org/10.1186/1471-244x-9-s1-s1
215. Fernández-Llimós, F., & Faus, M. J. (2005). From “drug-related problems” to “negative clinical outcomes”. American Journal of Health-System Pharmacy. https://doi.org/10.2146/ajhp050358
216. Fernández‐Jaén, A., Fernández‐Mayoralas, D. M., Perrone, A. L. F., Pérez, B. C., Albert, J., Martín, S. L., & Arribas, S. L. (2016). Disfunción en el trastorno por déficit de atención/hiperactividad: evaluación y respuesta al tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.62s01.2015527
217. Finer, M. J. (1971). Diphenylhydantoin For Treatment of Alcohol Withdrawal Syndromes. JAMA. https://doi.org/10.1001/jama.1971.03180140083024
218. Fink, G. (2015). Posttraumatic Stress Disorder: Introduction to Special Issue. Journal of Trauma & Treatment. https://doi.org/10.4172/2167-1222.s4-009
219. Finsterer, J., & Zarrouk‐Mahjoub, S. (2013). Fatigue in Healthy and Diseased Individuals. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909113494748
220. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
221. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
222. Forsyth, R., & Newton, R. (2017). Signs and symptoms. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198784449.003.0003
223. Franjić, S. (2023). Post-Traumatic Stress Disorder Appears as a Traumatic Experience. https://doi.org/10.61440/jcpn.2023.v1.04
224. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
225. Franz, M. R., & Schepank, H. (1997). [Mood disorders. Prevalence and course of unspecified functional disorders from the epidemiologic and psychosomatic viewpoint].. PubMed.
226. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
227. Freitas, D. F. D., Teixeira-Ribeiro, R., Bouça, J., Fernandes, N., Duarte, J., & Morgado, P. (2015). Metformin-induced Psychosis: a Case Report.. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31423-1
228. Frommberger, D.-B. U. (2014). In Reply. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0489c
229. Funk, S. (2013). [Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].. PubMed.
230. Fw, K. (1994). [Cannabis and psychoses].. PubMed.
231. Galanter, M. (2014). Network Therapy for Substance Use Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg60
232. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
233. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
234. Garrabé, J., & Cousin, F. (2012). Acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0081
235. Garza-Treviño, E. S. (1988). El manejo de urgencia de los cuadros psicóticos agudos. Salud Mental.
236. Gaszner, G., Barna, G., & Döme, P. (2017). [About the association between antipsychotic medication and cardiovascular morbidity: epidemiology and possible background mechanisms].. PubMed.
237. Gaudiano, B. A. (2012). The Need to Develop Innovative Interventions to Improve Treatment Adherence in Co-Occurring Severe Mental Illness and Substance Use Disorders. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.s8-e001
238. Genazzani, A. D., Ricchieri, F., Lanzoni, C., Strucchi, C., & Jasonni, V. M. (2006). Diagnostic and Therapeutic Approach to Hypothalamic Amenorrhea. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1365.009
239. George, O., & Koob, G. F. (2017). Individual differences in the neuropsychopathology of addiction. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.3/gkoob
240. George, O., Ahmed, S. H., & Gilpin, N. W. (2022). Are we compulsively chasing rainbows?. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01419-w
241. Ghoneim, M. M., & Block, R. I. (2012). Clinical, methodological and theoretical issues in the assessment of cognition after anaesthesia and surgery. European Journal of Anaesthesiology. https://doi.org/10.1097/eja.0b013e328356bd6e
242. Ghosh, S., Singha, P. S., & Ghosh, D. (2023). Neuroprotective compounds from three common medicinal plants of West Bengal, India: a mini review. Exploration of neuroscience. https://doi.org/10.37349/en.2023.00030
243. Giannuzzi, R., Testa, A. C., Sollazzo, F., Petrongolo, L., Bernardini, L., & Dain, S. (2013). Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases.. PubMed.
244. Gill, C. E., & Kompoliti, K. (2019). Clinical Features of Tourette Syndrome. Journal of Child Neurology. https://doi.org/10.1177/0883073819877335
245. Glance, J., Gopalan, P., & Ackerman, K. D. (2015). Substance Intoxication and Withdrawal States in the General Medical Setting. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199329311.003.0016
246. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
247. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
248. Goldstein, A. (2001). The Seesaw Brain: "Highs" and Adaptations. Addiction. https://doi.org/10.1093/oso/9780195146639.003.0006
249. Goldstein, T. R. (2010). Bipolar Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0134
250. Golubtsova, L. I., & Vasil'chenko, G. S. (1988). [Sexual disorders in women with slowly progressing schizophrenia].. PubMed.
251. González, S. M. B., Campoy, A. T., Carballeda, J. M., Pastorelli, R. V., & Vallejo, J. V. G. (2011). ¿Manía vs psicosis tóxica vs trastornos de conducta? A propósito de un caso.. Psiquiatria.com.
252. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
253. Gorwood, P. (1999). [Alcohol dependence and depression].. PubMed.
254. Grant, I., Sacktor, N., & McArthur, J. C. (2005). HIV neurocognitive disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0035
255. Graziani, P. (2011). La consommation excessive d’alcool chez la personne âgée. Drogues santé et société. https://doi.org/10.7202/1005300ar
256. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
257. Grossman, M. N. (2021). Several weeks of low mood, decreased appetite, and poor sleep after changing schools. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0007
258. Grover, C. A., Sturgill, D., & Goldman, L. (2022). Post–acute Withdrawal Syndrome. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000001047
259. Grover, S., Sarkar, S., & Avasthi, A. (2022). Clinical Practice Guidelines for Management of Medical Emergencies Associated with Psychotropic Medications. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_1013_21
260. Grover, S., Sarkar, S., & Avasthi, A. (2022). Management of Systemic Medical Emergencies Associated with Psychotropic Medications. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_1014_21
261. Guasch, M., & Soler, P. (2002). Tratamiento farmacológico: la desintoxicación. Adicciones. https://doi.org/10.20882/adicciones.536
262. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
263. Gull, D. G., & Langford, N. (2006). Drugs and driving. Adverse Drug Reaction Bulletin. https://doi.org/10.1097/00012995-200606000-00001
264. Gupta, K., & Mamidi, P. (2015). Kaphaja unmada: Myxedema psychosis?. International Journal of Yoga - Philosophy Psychology and Parapsychology. https://doi.org/10.4103/ijny.ijoyppp_10_16
265. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
266. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
267. Guthrie, E., & Nayak, A. (2012). Medically unexplained symptoms.
268. Gutiérrez-Achury, A. M., Vanegas-Vidal, M., Salazar-Díaz, L. I., & Arías, G. M. A. (2009). Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v1i2.43
269. Gutton, P. (1980). [Adolescence and acting (author's transl)].. PubMed.
270. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
271. Haaz, S., & Gache, P. (2007). [Medical stakes and prospects in alcohol use amongst the elderly].. PubMed.
272. Hadi, I., Wijayati, F., Usman, R. D., & Rosyanti, L. (2017). Major Depressive Disorder: A Mini Review. Health Information Jurnal Penelitian. https://doi.org/10.36990/hijp.v9i1.102
273. Hainline, B., Gurin, L., & Torres, D. M. (2019). Concussion Two Weeks Later. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0007
274. Hansell, N. (1975). Sympathomimetics and Schizophrenia. JAMA. https://doi.org/10.1001/jama.1975.03260250012002
275. Hasin, D. S., Grant, B. F., Harford, T. C., & Endicott, J. (1988). The Drug Dependence Syndrome and Related Disabilities. British Journal of Addiction. https://doi.org/10.1111/j.1360-0443.1988.tb00452.x
276. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
277. Hegel, M. T., Stanley, M. A., & Arean, P. E. (2002). Minor Depression and 'Subthreshold' Anxiety Symptoms in Older Adults: Psychosocial Therapies and Special Considerations. Generations.
278. Hensley, P. L., & Clayton, P. J. (2013). Why the Bereavement Exclusion Was Introduced in <i>DSM-III</i>. Psychiatric Annals. https://doi.org/10.3928/00485713-20130605-04
279. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
280. Hidayat, L. S., & Kristiana, I. F. (2023). Religiosity and Mental Health: A Case Study. Proceedings of International Conference on Psychological Studies (ICPsyche). https://doi.org/10.58959/icpsyche.v4i1.59
281. Hill, K. (2021). A fear of dogs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0011
282. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
283. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
284. Hodges, J. R. (2010). Alzheimer’s disease and other dementias. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.2442
285. Holgate, S. T. (2002). Considerations on third generation antihistamines. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01339.x
286. Hollister, L. E. (1977). Withdrawal From Benzodiazepine Therapy. JAMA. https://doi.org/10.1001/jama.1977.03270410032003
287. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
288. Hong, C. (2013). 조현병 스펙트럼 및 기타 정신병적 장애, 성격장애. 한국심리학회 학술대회 자료집.
289. Hoque, R., & Chesson, A. L. (2010). Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis.. PubMed.
290. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
291. Houde, S. C., & KAMPFE-LEACHER, R. (1997). Chronic Fatigue Syndrome. The Nurse Practitioner. https://doi.org/10.1097/00006205-199707000-00003
292. Howard, M. O., Garland, E. L., Sharp, C. W., & Beauvais, F. (2015). Substance Abuse: Inhalant‐Related Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch77
293. Howland, R. H. (2010). Potential Adverse Effects of Discontinuing Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20100527-98
294. Howland, R. H. (2010). Potential Adverse Effects of Discontinuing Psychotropic Drugs. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20100730-04
295. Huda, A. S. (2019). Social factors and health. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198807254.003.0013
296. Hudler, G. W., & Sinclair, W. A. (1988). Tree Declines: Four Concepts of Causality. Arboriculture & Urban Forestry. https://doi.org/10.48044/jauf.1988.009
297. Hughes, J. R., Higgins, S. T., & Bickel, W. K. (1994). Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03744.x
298. Hulse, G. K. (2002). Alcohol, drugs and much more in later life. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462002000500008
299. Hulse, G. K., Lautenschlager, N. T., Tait, R. J., & Almeida, O. P. (2005). Dementia associated with alcohol and other drug use. International Psychogeriatrics. https://doi.org/10.1017/s1041610205001985
300. Huprich, S. K. (2010). Schizoid Personality Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0819
301. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
302. Håkansson, A., & Johansson, B. (2015). Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0678-5
303. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
304. Inmaculada, M., & Pérez, P. B. (2016). Neuronal and behavioural effects of social isolation in old age.
305. Is, B., Golovoda, A., Pneumaticos, S. G., & Vlamis, J. (2021). The effect of depression in hospitalization and rehabilitation of patients with spinal cord injury. Acta Orthopaedica Et Traumatologica Hellenica.
306. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews.
307. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(25)07083-8
308. Isenberg, K., & Garcia, K. S. (2008). Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Caused by a General Medical Condition. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-252-6_2
309. Isfahani, H. F. (2007). Tinjauan hukum pidana Islam terhadap pasal 59 ayat (2) uu nomor 5 tahun 1997 tentang psikotropika: studi analisis pidana mati bagi pengedar psikotropika golongan I.
310. Ishizuka, K., Shikino, K., Li, Y., Yokokawa, D., Tsukamoto, T., Yanagita, Y., Kojima, J., Yamashita, S., Noda, K., Uehara, T., & Ikusaka, M. (2023). The differential diagnosis of medical and psychogenic disease in primary care. Journal of General and Family Medicine. https://doi.org/10.1002/jgf2.661
311. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
312. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
313. Jacobs, D. H. (2007). Psychiatric Drugging: Forty Years of Pseudo-Science, Self-Interest, and Indifference to Harm.
314. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
315. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
316. Jensen, C., Lukow, H. R., & Heck, A. (2012). Identifying Barriers to Care for Older Adults with Substance Use Disorders and Cognitive Impairments. Alcoholism Treatment Quarterly. https://doi.org/10.1080/07347324.2012.663302
317. Jevtovic, J., Jovanović, J., Grujicic, M. V. –., & Vujcic, J. (2021). OCCUPATIONAL STRESS IN COMPUTER OPERATORS. Knowledge International Journal.
318. Ji, J. (2012). Distinguishing subclinical (subthreshold) depression from the residual symptoms of major depression.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2012.05.007
319. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
320. Johnson, B. A. (1990). Psychopharmacological effects of cannabis.. PubMed.
321. Johnson, L. K. (1989). How to Diagnose and Treat CHEMICAL DEPENDENCY in the Elderly. Journal of Gerontological Nursing. https://doi.org/10.3928/0098-9134-19891201-07
322. Jones, E. M., Knutson, D., & Haines, D. (2003). Common problems in patients recovering from chemical dependency.. PubMed.
323. Juruena, M. F. (2012). Understanding subthreshold depression.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2012.05.009
324. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
325. Kane, J. M., & Mayerhoff, D. (1989). Do Negative Symptoms Respond to Pharmacological Treatment?. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000291630
326. Kanellopoulos, D., & Vallejo, P. S.-B. (2019). Substance Related Cognitive Dysfunction in Aging. Clinical handbooks in neuropsychology. https://doi.org/10.1007/978-3-319-93497-6_19
327. Kapała, W., Kapała, A., & Wojtyła-Buciora, P. (2023). Psychoactive Substances and Selected Health Problems Related to Their Use. https://doi.org/10.2478/bgbl-2023-0036
328. Kapfhammer, H. (2011). CS03-04 - Concept of somatoform disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)73481-2
329. Kaplan, H., Sadock, B. J., & Cancro, R. (1991). Comprehensive Textbook of Psychiatry/V.. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-114-9-823_8
330. Kaplan, H., Sadock, B. J., & Grebb, J. A. (1994). Kaplan and Sadock's synopsis of psychiatry : behavorial sciences, clinical psychiatry. Williams & Wilkins eBooks.
331. Karakatsoulis, G. N., Tsapakis, E.-M., & Fountoulakis, K. Ν. (2021). Clinical characteristics and treatment of treatment-resistant bipolar depression. Psychiatriki. https://doi.org/10.22365/jpsych.2021.048
332. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
333. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
334. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
335. Kasatkin, D. S. (2006). [Possible mechanisms of chronic fatigue syndrome in multiple sclerosis].. PubMed.
336. Kaware, M. A. S., Dudhe, M. P. V., Chavhan, M. N. R., Naveria, M. A., & Rajeshwari, K. R. (2024). An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it’s Interaction with Other Drugs which are Already in use Respect to Other Disease. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-18578
337. Kayser, B., & Gremion, G. (2004). Chronic fatigue and loss of performance in endurance athletes: overtraining. Schweizerische Zeitschrift für Sportmedizin und Sporttraumatologie.
338. Kazamatsuri, H. (1994). [Symptomatology and diagnosis of manic-depressive illness].. PubMed.
339. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
340. Kennedy, N. (2004). ACU Column 15.4 (November 2004): Connected Separateness or Separate Connection: Envisioning Body with Mind. Journal of Health Care for the Poor and Underserved. https://doi.org/10.1353/hpu.2004.0063
341. Kerfoot, M. (2005). Partnerships between health and local authorities. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508441.003.0008
342. Khadse, V. S. C. (2022). Free Papers Compiled. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.341792
343. Khalafian, A., Dukes, C., & Tucker, P. (2015). Consultation Dilemma Catatonia in a Patient with Prior TBI: MentaI or Medical Disorder?. PubMed.
344. Khan, A. Y., Kalia, R., Ide, G. D., & Ghavami, M. (2017). What Are Realistic Treatment Goals? Lingering Symptoms Require You to Evaluate Pharmacotherapy and Offer Psychosocial Interventions. Current psychiatry.
345. Khantzian, E. J. (1990). Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences.. PubMed.
346. Khoury, N. J. (1968). When Alcoholics Stop Drinking. Postgraduate Medicine. https://doi.org/10.1080/00325481.1968.11693285
347. Killick, L., Carlyle, W., & Ancill, R. (1991). ECT: An Effective Treatment in the Screaming Demented Patient. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1991.tb03610.x
348. Kintz, P., Blanchot, A., Farrugia, A., & Goullé, J. (2025). [Toxicological aspects of chemical submission].. PubMed.
349. Kirakosyan, G. (2022). Understanding psychosis: diagnosis and clinical presentation (updates for clinicians). World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2022.13.1.0759
350. Kircus, E., & Brillhart, B. (1990). Dealing with Substance Abuse Among People with Disabilities. Rehabilitation Nursing. https://doi.org/10.1002/j.2048-7940.1990.tb01487.x
351. Kirsch, J., Simeon, D., Berlin, H. A., & Hollander, E. (2015). Disruptive, Impulse Control, and Conduct Disorders: Intermittent Explosive Disorder, Kleptomania, and Pyromania. Psychiatry. https://doi.org/10.1002/9781118753378.ch70
352. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
353. Klega, A. E., & Keehbauch, J. (2018). Stimulant and Designer Drug Use: Primary Care Management.. PubMed.
354. Kloft, L., Monds, L. A., Blokland, A., Ramaekers, J. G., & Otgaar, H. (2021). Hazy memories in the courtroom: A review of alcohol and other drug effects on false memory and suggestibility. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2021.02.012
355. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
356. Knight, E., & McIntyre, A. (2012). Pharmacy medications and driving: delivering key information to ageing drivers.
357. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
358. Koch‐Weser, J., Thompson, T. L., Moran, M. G., & Nies, A. S. (1983). Psychotropic Drug Use in the Elderly. New England Journal of Medicine. https://doi.org/10.1056/nejm198301273080405
359. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2015). A Case of Cannabis Use-Associated Psychotic Disorder Accompanied by Autoscopic Phenomena. Addicta The Turkish Journal on Addictions. https://doi.org/10.15805/addicta.2015.2.1.061e
360. Kokurcan, A., & Atbaşoğlu, C. (2015). [Differential Diagnosis of Schizophrenia: Psychotic Symptoms in Neurodevelopmental Disorders and Psychotic Disorders due to other Medical Conditions].. PubMed.
361. Kondo, T., & Ishiguchi, H. (2007). 3. Drug Induced Dyskinesia. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.96.1621
362. Koob, G. F., Kandel, D. B., & Volkow, N. D. (2008). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9780470515167.ch22
363. Koob, G. F., Kandel, D. B., Baler, R., & Volkow, N. D. (2015). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9781118753378.ch22
364. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
365. Koçak, Ö., & Koçak, S. (2023). Underrated Diagnosis: Prenatal Depression. Kafkas Journal of Medical Sciences. https://doi.org/10.5505/kjms.2023.21033
366. Krahn, L. E., MD, & Jowsey‐Gregoire, S. G. (2006). Psychiatry. CRC Press eBooks. https://doi.org/10.1201/b21610-26
367. Krüger, R. T. (2024). Addiction Disorders. Psychodrama in Counselling, Coaching and Education. https://doi.org/10.1007/978-981-99-7508-2_10
368. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
369. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
370. Kumagai, R., & Iseki, E. (2012). [Psychotropic medication of elderly patients].. PubMed.
371. Kwak, K. H. (2010). Emergence agitation/delirium: we still don't know. Korean journal of anesthesiology. https://doi.org/10.4097/kjae.2010.59.2.73
372. Lader, M. (1999). Some adverse effects of antipsychotics: prevention and treatment.. PubMed.
373. Lafortune, G., Richardson, D., Sassi, F., Cecchini, M., Looper, M. D., Fujisawa, R., Dumont, J., Paris, V., Balestat, G., Notzon, F., Brownwood, I., Sandra, G., Armesto, N., Klazinga, S., Morgan, D., Astolfi, R., & Cave, W. (2009). Suicide. Health at a glance. https://doi.org/10.1787/health_glance-2009-9-en
374. Lam, R. W. (2012). Clinical features and diagnosis. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199692736.003.0004
375. Lane, R., & Baldwin, D. S. (1997). Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199706000-00012
376. Latas, M., Jerotić, S., Tiosavljević, D., & Lačković, M. (2023). Separation Anxiety Disorder: Is There a Justification for a Distinct Diagnostic Category?. Mind Brain and Education. https://doi.org/10.1007/978-3-031-33013-1_7
377. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
378. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
379. Lee, X.-C., Lu, T., Zheng, W., & Xue, Y. (2025). STRESS COMBINED WITH EXTINCTION PREVENTS COCAINE RELAPSE BY DISRUPTING MEMORY. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.175
380. Lemogne, C., Pitron, Jy, R., Limosin, F., & Cathébras, P. (2019). What attitude towards a patient with somatoform disorder?. PubMed.
381. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
382. ling, Z. G. (2014). 抑郁症的低动力症状特点. Chin J Psychiatry. https://doi.org/10.3760/cma.j.issn.1006-7884.2014.02.013
383. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
384. Lobo, A., Saz, P., Quintanilla, M., & Gracia‐García, P. (2018). Dementia. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl05
385. Looper, M. D., Lafortune, G., Balestat, G., Gool, K. V., Biondi, N., & Mueller, M. (2012). Suicide. Health at a glance. Europe. https://doi.org/10.1787/9789264183896-10-en
386. Lozano, R. P., García, Y. Á., Tafalla, D. B., & Albaladejo, M. F. (2007). Cafeína: un nutriente, un fármaco, o una droga de abuso. Adicciones. https://doi.org/10.20882/adicciones.303
387. Luca, L., & Crocco, E. (2022). It’s just a nightcap. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197521670.003.0028
388. Luft, A. R. (2008). Critical Care Seizures Related to Illicit Drugs and Toxins. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-841-0_13
389. Luis, T. J. (2021). Psychotropic drugs prescription block the positive effects of the doctor-patient communication and relationship. Archives of Psychiatry and Mental Health. https://doi.org/10.29328/journal.apmh.1001029
390. López, S. S. D. M., & Márquez, J. (2016). Evolución y situación actual del consumo deantidepresivos en España.
391. López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022). 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.990405
392. Machado, C. F. A., & Siqueira, E. C. D. (2022). Uma abordagem geral do Transtorno de Estresse Pós-Traumático: revisão de literatura. Revista Eletrônica Acervo Médico. https://doi.org/10.25248/reamed.e10939.2022
393. Machado, G. G., Miranda, E., Moraes, C. S., Balsan, I. S. G., Bonini, L. V., Siqueira, V., Machado, E. L. J. D., Santos, A. D. D., Campelo, I. K. B., Melo, M. J. O. F. D., Conceição, M. V. D. P. D., Lopes, J. D. V., D’Ângelo, I. F. B., Silva, L. R. S., & Oliveira, M. V. A. D. (2024). ANÁLISE DAS TERAPIAS MEDICAMENTOSAS NA CONDUTA DA ESQUIZOFRENIA. Revista Contemporânea. https://doi.org/10.56083/rcv4n5-244
394. Maddocks, I., & Macleod, A. D. (2018). Psychopharmacology. CRC Press eBooks. https://doi.org/10.4324/9781315385532-16
395. Maeda, H., Ishikawa, T., & Michiue, T. (2010). Biochemical investigation for clinical diagnosis of drug dependence.
396. Mahadevan, J., D’cruz, M., Chand, P., & Murthy, P. (2019). An interesting presentation of psychotic catatonia in an elderly patient with alcohol dependence. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_33_19
397. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
398. Mahon, S. M., & Carr, E. (2021). Fatigue/Lack of Endurance: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.25
399. Mailman, R. B., & Murthy, V. (2010). Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?. Current Pharmaceutical Design. https://doi.org/10.2174/138161210790361461
400. Maj, M. (2023). Understanding depression beyond the “mind‐body” dichotomy. World Psychiatry. https://doi.org/10.1002/wps.21142
401. Maldonado, J. R., & Spiegel, D. (2015). Dissociative Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch61
402. Malin, H., & Saleh, F. M. (2007). Paraphilias: Clinical and Forensic Considerations.
403. Manysheva, K., Sherman, M. A., Zhukova, N. V., & Kopishinskaia, S. (2022). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: First Described Complication after Gam-COVID-Vac Vaccine.. PubMed.
404. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
405. Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023). Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients. https://doi.org/10.1007/978-3-031-30093-6_4
406. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
407. Marich, J., & Dansiger, S. (2021). Healing Addiction with EMDR Therapy. https://doi.org/10.1891/9780826136077
408. Marouf, R., Chtioui, H., Girardin, F., Buclin, T., & Diezi, L. (2024). Pharmacovigilance. Sevrage et effet rebond: pas seulement avec les psychotropes. Revue Médicale Suisse. https://doi.org/10.53738/revmed.2024.20.856-7.96
409. Martin, K. A. (2021). Miscellaneous Psychiatric Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0043
410. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
411. Mateu, I. L., Cantalejo, C. N., Martínez, J. M., Nivela, H. G., Lázaro, V. C., & Perales, C. R. (2025). DROGAS Y ESQUIZOFRENIA. ARTÍCULO MONOGRÁFICO.. Revista sanitaria de investigación.. https://doi.org/10.34896/rsi.2025.44.22.002
412. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
413. Mauri, M., & Ramacciotti, D. (2006). Sintomi Psichici e Somatici dei Disturbi dell'Umore: razionali di terapia. Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology.
414. Maxwell, R. A., & Eckhardt, S. B. (1990). Imipramine. Drug Discovery. https://doi.org/10.1007/978-1-4612-0469-5_10
415. McArdle, P., & Angom, B. (2012). Adolescent substance misuse: an update on behaviours and treatments. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.106.003327
416. McMurran, M. (2012). Other Personality Disorders. https://doi.org/10.1002/9781118156391.ebcp002023
417. Mederos, M. M. A., Rojas, A. M., & Hidalgo, A. A. (2012). EVALUACIÓN DE TÉCNICAS ELECTROFISIOLÓGICAS EN EL DIAGNÓSTICO DEL SÍNDROME DEL TÚNEL CARPIANO. DOAJ (DOAJ: Directory of Open Access Journals).
418. Medina, S., & Fernando, D. (2019). Caso Christopher : El deseo, de deseo imposible en la neurosis obsesiva..
419. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
420. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
421. Meehan, T. J., Bryant, S. M., & Aks, S. E. (2010). Drugs of Abuse: The Highs and Lows of Altered Mental States in the Emergency.
422. Melamed, E., Friedberg, G., & Zoldan, J. (1999). Psychosis: impact on the patient and family.. PubMed.
423. Melville-Drewes, A. (2018). Posttraumatische Verbitterungsstörung, Burn-out ... – arbeitsplatzbezogene psychische Störungen in der amtsärztlichen Begutachtung. Das Gesundheitswesen. https://doi.org/10.1055/s-0038-1639183
424. Meza-Ruiz, W., & Zúñiga-Escobar, G. (2023). Hematoma cerebral intraparenquimatoso e intraventricular por cocaína: reporte de un caso. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272023000100064
425. Mezquida, G., Savulich, G., Atkinson, S., Bernardo, M., & Fernández-Egea, E. (2018). S69. A CASE STUDY OF CLOZAPINE AND COGNITION: FRIEND OR FOE?. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby018.856
426. Michal, M. (2022). Depersonalization/Derealization Disorder. Routledge eBooks. https://doi.org/10.4324/9781003057314-29
427. Micoulaud‐Franchi, J., Lemogne, C., & Quilès, C. (2019). [Definition of somatoform disorders: somatic symptoms or mental symptoms?]. PubMed.
428. Mihanović, M., Bodor, D., Kezić, S., Restek-Petrović, B., & Silić, A. (2009). Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders.. PubMed.
429. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
430. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
431. Miller, R. L., & Mason, S. E. (2011). Diagnosing Schizophrenia. Columbia University Press eBooks. https://doi.org/10.7312/columbia/9780231150415.003.0006
432. Minton, C. A. B., Bruner, S. M., & Morris, C. A. W. (2017). Diagnosis and Treatment of Children and Adolescents. Routledge eBooks. https://doi.org/10.4324/9781315466736-15
433. Mir, J. A., Mushtaq, B., & Mushtaq, O. A. (2022). Clinical case report on bipolar affective disorder, mania. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.007
434. Miwa, Y., Yanai, R., Fuyuya, H., Ohtsuka, K., & Kasama, T. (2012). [How to use of the psychotropic drug in rheumatic disease].. PubMed.
435. Miyata, H., Kono, J., & Yanagita, T. (2005). Clinical features of nicotine dependence.
436. Moh, D., & Sansone, R. A. (2015). Factitious Disorder Manifesting as Hematemesis and Hematochezia. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.14l01693
437. Mohr, P. (2022). Treating Catatonia: a Blind Spot of Psychiatry?. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.143
438. Molero‐Chamizo, A. (2005). 3,4-metilenodioximetanfetamina (‘éxtasis’): efectos emocionales y cognitivos a largo plazo y depleción serotoninérgica. Revista de Neurología. https://doi.org/10.33588/rn.4102.2004547
439. Monteiro, M. I., Ferreira, A., Grebe, H., Gomes, L., & Costa, M. M. D. (2016). Psiquiátrico, aditivo ou orgânico:  um desafio nos adolescentes. DOAJ (DOAJ: Directory of Open Access Journals).
440. Moore, D. P., & Puri, B. K. (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E.
441. Moreno, M. A. G., Torres, M. Á. G., & Gaviria, M. (2015). Trastornos afectivos estacionales, "winter blues". Revista de la Asociación Española de Neuropsiquiatría. https://doi.org/10.4321/s0211-57352015000200010
442. Morse, D. R., Martin, J. S., & Moshonov, J. (1991). Psychosomatically induced death: Relative to stress, hypnosis, mind control, and voodoo: Review and possible mechanisms. Stress Medicine. https://doi.org/10.1002/smi.2460070404
443. Mostel, E., Patel, S., & Wiener, B. G. (2022). A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. American Journal of Case Reports. https://doi.org/10.12659/ajcr.938268
444. Mucci, A., Bucci, P., Giordano, G. M., Brando, F., & Galderisi, S. (2021). Apathy in schizophrenia: assessment in clinical settings and overlap with other dimensions of impairment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.159
445. Mueller‐Pfeiffer, C., & Wittmann, L. (2013). Preliminary Investigation of the Reliability and Validity of the German Version of the State Scale of Dissociation (SSD). Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000106
446. Mufić, A. K., & Karlović, D. (2015). Cytochrome p4502D6 and Serotonin Transporter Polymorphism in Patient with Bipolar Disorder Type II.
447. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
448. Munster, B. C. V., Rooij, S. E. D., & Inouye, S. K. (2016). Delirium, drugs, toxins. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199655946.003.0022
449. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
450. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
451. Münster, T., & Tzabazis, A. (2013). Somatische Intervention und Demenz - Einfluss von Chirurgie und Anästhesie auf kognitive Funktionen. PSYCH up2date. https://doi.org/10.1055/s-0033-1343131
452. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
453. Nakata, C., Nara, K., Kinoshita, F., Kikuchi, K., & Asai, M. (2015). [Alcohol withdrawal syndrome showing various progress: A case report].. PubMed.
454. Namlı, Z., ÖZBAY, A., & Tamam, L. (2022). Yetişkin Ayrılma Anksiyetesi Bozukluğu: Bir Gözden Geçirme. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. https://doi.org/10.18863/pgy.940071
455. Nasrallah, H. A. (2015). Setting the Stage for Success or Failure. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.14016tx1c
456. Nassisi, D., Korc, B., Hahn, S. A., Bruns, J., & Jagoda, A. (2006). The evaluation and management of the acutely agitated elderly patient.. PubMed.
457. Nater, U. M., Miller, A. H., Reeves, W. C., & Raison, C. L. (2010). Chronic Fatigue Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0176
458. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
459. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
460. Nicolson, G. L., Nasralla, M. Y., Haier, J., & Nicolson, N. L. (1999). GULF WAR ILLNESSES: ROLE OF CHEMICAL, RADIOLOGICAL AND BIOLOGICAL EXPOSURES.
461. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
462. Norton, C., Williams, J., Taylor, C., Nunwa, A., & Whayman, K. (2008). Chapter 19 Bowel care and vulnerable groups. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199298655.003.0019
463. Norton, G. R., Block, G. W., & Malan, J. (1991). The Psychopathology of Panicking and Non-Panicking Male Alcoholics. Alcoholism Treatment Quarterly. https://doi.org/10.1300/j020v08n03_06
464. Ntchana, A. (2022). A Case of Brief Psychotic Disorder: An Unintended Consequence of COVID-19 Virus. American Journal of Biomedical Science & Research. https://doi.org/10.34297/ajbsr.2022.16.002239
465. Ntchana, A. (2022). A Case of Brief Psychotic Disorder: An Unintended Consequence of COVID-19 Virus. Psychology & Psychological Research International Journal. https://doi.org/10.23880/pprij-16000300
466. Nubukpo, P., Laot, L., & Clément, J. (2012). Addictive behaviors in the aged. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2012.0355
467. Nunes, F. D. D., Freitas, P. H. B. D., Pinto, J. A. F., Souza, A. R. S., & Machado, R. M. (2016). Análise da prevalência de Síndrome Metabólica e fatores de risco associados em pacientes com Esquizofrenia Refratária. 12º Congresso Internacional da Rede Unida.
468. Nuñez, M. B., Dhingra, A., Dhingra, M., Kossack, R., & Dhingra, M. (2022). Kratom's rising role in the potential exacerbation of mental health disorders: A case report and review of the literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100069
469. Obeso, J. Á., Guridi, J., & DeLong, M. R. (1997). Surgery for Parkinson's disease.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.62.1.2
470. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
471. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
472. Opielak, G., & Zuzak, T. (2018). Drugs used in palliative medicine. Hospice and Palliative Medicine International Journal. https://doi.org/10.15406/hpmij.2018.02.00069
473. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
474. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
475. O’Neil-Page, E., Anderson, P. R., & Dean, G. E. (2015). Fatigue. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244330.003.0001
476. Paidi, G., Jean, M., Oduwole, A., Gautam, N., Kapoor, K., & Paidi, R. (2022). Chronic Unexplained Vomiting: A Case Report on Psychogenic Vomiting. Cureus. https://doi.org/10.7759/cureus.25959
477. Palaniyappan, L., & Krishnadas, R. (2010). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199553617.003.0009
478. Palmer, R. M. (1990). 'Failure to thrive' in the elderly: diagnosis and management.. PubMed.
479. Pang, D., & Pucci, M. (2021). Medical Aspects of Drug and Alcohol Use. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623199.011
480. Panza, F., Capurso, C., D’Introno, A., Colacicco, A. M., Capurso, A., & Solfrizzi, V. (2006). PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2006.00874.x
481. Paradela, E. M. P. (2011). Depressão em idosos. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE). https://doi.org/10.12957/rhupe.2011.8850
482. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
483. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
484. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
485. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
486. Pedrós, A., Martí‐Almor, J., Gutiérrez, G., Tenías, J. M., & Ruescas, S. (2009). [Two-year diagnostic stability and prognosis in acute psychotic episodes].. PubMed.
487. Pereira, J. A. (2021). Teenager with paranoia and hallucinations preceded by a decline in academic and social functioning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0006
488. Pereira, S. M. P., Guimarães, S. K. G., Marques, A., & Borges, S. (2008). Electroconvulsivotherapy in the elderly, indications, risks and side-effects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.01.611
489. Perkinson, R. R., & Jongsma, A. E. (1997). The Chemical Dependence Treatment Planner.
490. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
491. Petruševičienė, D., & Kriščiūnas, A. (2003). [Occupational therapy for patients after stroke].. PubMed.
492. Petta, G. D. (2015). La "Psicosi Sintetica" da nuove sostanze psicoattive (NPS). Comprensione psicopatologica di un caso clinico. RIVISTA SPERIMENTALE DI FRENIATRIA. https://doi.org/10.3280/rsf2015-002008
493. Petzke, F., Tölle, T. R., Fitzcharles, M., & Häuser, W. (2021). Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs. https://doi.org/10.1007/s40263-021-00879-w
494. Phillips, M. R. (2009). Is distress a symptom of mental disorders, a marker of impairment, both or neither?. PubMed.
495. Pichler, W. J., & Pichler, C. E. (2009). DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). Allergologie. https://doi.org/10.5414/alp32365
496. Pickard, H. (2011). What Is Personality Disorder?. Philosophy, psychiatry & psychology. https://doi.org/10.1353/ppp.2011.0040
497. Pitchot, W., Scantamburlo, G., & Ansseau, M. (2013). [Psychiatric complications and addictions].. PubMed.
498. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
499. Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, К. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders. https://doi.org/10.1002/mds.23135
500. Popa, T., & Delcea, C. (2019). Voyeurism and Scopophilia. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.121
501. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
502. Potocnik, F. (2013). Dementia : The South African Society of Psychiatrists (SASOP) Treatment Guidelines for Psychiatric Disorders. South African Medical Journal.
503. Prajapati, B., Agarwal, A., Garg, D., Garg, A., Pandit, A., Radhakrishnan, D. M., & Srivastava, A. (2024). Delayed post-hypoxic parkinsonism with leukoencephalopathy associated with carbon monoxide poisoning. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_37_24
504. Prasad, A., Avinash, P., Victor, R., & Singhania, R. (2024). Revisiting the concept of nuclear schizophrenia: A case series from North India. Telangana Journal of Psychiatry. https://doi.org/10.4103/tjp.tjp_64_23
505. Pratibha, S. (2010). Etiology of Late Onset Seizures.
506. Prelipceanu, D., & Barbu, R. E. (2017). Burnout syndrome. Romanian Journal of Psychiatry & Psychotherapy. https://doi.org/10.37897/rjpp.2017.2.1
507. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
508. Provini, F., Lombardi, C., & Lugaresi, E. (2005). Insomnia in Neurological Diseases. Seminars in Neurology. https://doi.org/10.1055/s-2005-867074
509. Provini, F., Vetrugno, R., & Montagna, P. (2008). Restless legs syndrome: effects on cognitive functioning, memory, and psychomotor performance. CRC Press eBooks. https://doi.org/10.3109/9780203091715-54
510. Pulia, M. S., & Richmond, J. S. (2013). The patient with post-traumatic stress disorder in the emergency department. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.016
511. Pytell, J. D., & Rastegar, D. A. (2025). Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0009
512. Pérez, S., & Reinaldo, A. (2017). Biomarcadores de estrés e inflamación en la psicosis temprana. TDX (Tesis Doctorals en Xarxa).
513. Pérez, Y. M. M., Ortega, D. L. G., & Torres, S. V. L. (2022). AGITACIÓN PSICOMOTRIZ. PUERTO MADERO EDITORIAL eBooks. https://doi.org/10.55204/pmea.3.c10
514. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03743.x
515. Quartini, A., Pacitti, F., Bersani, G., & Iannitelli, A. (2018). From Adolescent Neurogenesis to Schizophrenia: Opportunities, Challenges and Promising Interventions. Biomedical Reviews. https://doi.org/10.14748/bmr.v28.4452
516. Rabi-Žikić, T., Nedić, A., Žarkov, M., Slankamenac, P., Dobrenov, D., & Živanović, Ž. (2009). Poststroke depression: Diagnosis of depression, phenomenology and specificity of depressive symptoms. Medicinski pregled. https://doi.org/10.2298/mpns0904148r
517. Rabinak, C. A., & Nirenberg, M. J. (2010). Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneurol.2009.294
518. Rachmani, S., & Mayasari, D. (2017). Kombinasi Farmakoterapi dan Psikoterapi Pada Pengobatan Episode Depresif Sedang Dengan Gejala Somatis. Jurnal Medula.
519. Rahman, M. M., & Rabin, F. (2022). Assessment of Psychiatric Issues in Post-concussion Syndrome. Journal of Biomedical Research & Environmental Sciences. https://doi.org/10.37871/jbres1392
520. Rahmani, M., Ahmadi, S., & Moghaddam, H. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose.
521. Rahmani, S. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose Methamphetamine. Journal of Clinical Toxicology. https://doi.org/10.4172/2161-0495.1000111
522. Raičević, B., Janković, S. V., Gojak, R., Dabanović, V., & Јаnkovic, S. (2023). Long-term outcomes in refractory status epilepticus. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2023.2292143
523. Raja, M., & Azzoni, A. (2009). Suicidal Ideation Induced by Episodic Cannabis Use. Case Reports in Medicine. https://doi.org/10.1155/2009/321456
524. Ramos, B. R. M., Martins, F. S., & Osório, E. (2022). Psychotic Cannabis Withdrawal: A Clinical Case. Cureus. https://doi.org/10.7759/cureus.31465
525. Rani, M. K. S., Fathima, S. T., Gayathri, S. L., Pavani, M., & Swathi, Y. (2022). Detection of Autism Spectrum Disorder using Machine Learning. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-7600
526. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
527. RASHID, A. M. (2021). COMPULSIVE PHOBIA AND HOW TO TREAT IT IN THE LIGHT OF THE HOLY QURAN. https://doi.org/10.47832/rimarcongress3-11
528. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
529. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
530. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
531. Realpe, B. L. C. (2013). Estudio comparativo de la acción psicofarmacológica y analgésica de extractos de plantas de uso terapéutico tradicional con antidepresivos inhibidores selectivos de la recaptación de monoaminas.
532. Renemane, L., Vrubļevska, J., & Cera, I. (2022). First Episode Psychosis Following COVID-19 Vaccination: a Case Report.. PubMed.
533. Reuber, M., Schachter, S. C., Elger, C. E., & Altrup, U. (2009). Conditions Associated With Epilepsy. https://doi.org/10.1093/oso/9780195379532.003.0005
534. Riofrío, I. P. B., Jefe, M., De, D., Mental, S., Miller, H., Mt, S., Psiquiatría, D., Dra, H., Velastegui, G. N. J., medico, Psc, R., Alexandra, C., & Torres, L. (2019). Síndrome Neuroléptico Maligno: A propósito de un caso clínico. https://doi.org/10.36015/cambios.v16.n1.2017.279
535. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
536. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.3917/rne.043.0196
537. Roberts, A. J., & Koob, G. F. (1997). The neurobiology of addiction: an overview.. PubMed.
538. Rodas, P. A. V., & Pena, M. (2024). Prevalência da alteração de capacidade funcional, síndrome de fragilidade e sarcopenia em pacientes com mais de 60 anos atendidos na Associação Fluminense de Reabilitação. Acta Fisiátrica. https://doi.org/10.11606/issn.2317-0190.v31isupl.1a225105
539. Rodrigues, F. D. A. A. (2022). WHAT HAPPENS IN THE BRAIN OF A PERSON WITH DISORDER. International Journal of Health Science. https://doi.org/10.22533/at.ed.1592442202087
540. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
541. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
542. Roessner, V., & Rothenberger, A. (2014). Tic Disorders. https://doi.org/10.1007/978-3-7091-1501-5_27
543. Rogers, N. L., & Kloss, J. D. (2004). Medical Conditions and Diseases. CRC Press eBooks. https://doi.org/10.3109/9780203998007-6
544. Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults.. Journal of Abnormal Psychology. https://doi.org/10.1037/0021-843x.100.2.214
545. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
546. Rowbotham, M. C., & Lowenstein, D. H. (1990). Neurologic Consequences of Cocaine Use. Annual Review of Medicine. https://doi.org/10.1146/annurev.me.41.020190.002221
547. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
548. Roy‐Byrne, P. (2008). Cannabis Withdrawal Syndrome: Reefer Madness?. Journal watch. https://doi.org/10.1056/jp200810270000004
549. Rudolf, J., Grond, M., Neveling, M., & Heiß, W.-D. (1999). Catatonía en la enfermedad de Graves. European psychiatry (Ed Española). https://doi.org/10.1017/s1134066500000060
550. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
551. Sahoo, S., Panigrahi, H., Rao, B. N. B., & Sudhakar, D. (2013). PSYCHOLOGICAL PROBLEMS OF THE AGED AND ITS MANAGEMENT. International Journal of Research in Ayurveda and Pharmacy. https://doi.org/10.7897/2277-4343.04505
552. Saifuddin, T. M., Wei, C. W., Ismail, A. F., & Harun, N. A. (2018). Alcohol-Induced Psychotic Disorder with Suicidal Attempt: A Case Report. The Malaysian journal of psychiatry.
553. Saitz, R. (1998). Introduction to alcohol withdrawal.. PubMed.
554. Salaspuro, M. (2009). [Intoxicated patient at the emergency department and referral to treatment].. PubMed.
555. Sansone, R. A., & Sansone, L. A. (2010). SSRI-Induced Indifference.. PubMed.
556. Sansone, R. A., & Sansone, L. A. (2015). BORDERLINE PERSONALITY DISORDER IN THE MEDICAL SETTING: Suggestive Behaviors, Syndromes, and Diagnoses.. PubMed.
557. Sarkar, S., & Dinesh, M. (2023). The threshold problem of impairment criteria in psychiatric diagnosis. Journal of SAARC Psychiatric Federation. https://doi.org/10.4103/jspf.jspf_12_23
558. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
559. Sarzi‐Puttini, P., Atzeni, F., Lanata, L., Bagnasco, M., Colombo, M. M., Fischer, F., & d’Imporzano, M. (2011). Pain and ketoprofen: what is its role in clinical practice?. Reumatismo. https://doi.org/10.4081/reumatismo.2010.172
560. Sawarkar, A., Shambharkar, R., Shambharkar, M., Khandar, J., Sakharwade, P., & Kasturkar, P. (2021). Case Report on Acute Transient Psychotic Disorder. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i45b32783
561. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
562. Schildkrout, B. (2014). Disease #18: Hepatic Encephalopathy. https://doi.org/10.1002/9781394260447.ch46
563. Schildkrout, B. (2014). Disease #34: Mercury Poisoning. https://doi.org/10.1002/9781394260447.ch62
564. Schildkrout, B. (2014). Disease #57: <scp>REM</scp> Sleep Behavior Disorder. https://doi.org/10.1002/9781394260447.ch85
565. Schildkrout, B. (2014). Disease #58: Restless Legs Syndrome. https://doi.org/10.1002/9781394260447.ch86
566. Schneck, H., & Rupreht, J. (1989). Central anticholinergic syndrome (CAS) in anesthesia and intensive care.. PubMed.
567. Schröder, A., Høeg, M. D., & Fink, P. (2013). [Subjective dizziness].. PubMed.
568. Schwartz, R. H. (1984). Psychoactive Drug Use During Adolescence: The Pediatrician's Role. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1984.02140400083021
569. Schäfer, I., Kurth, R., & Gerhardt, H. (2011). Posttraumatische und psychotische Symptome bei schwer traumatisierten Patienten. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0031-1281801
570. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
571. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
572. Seiner, S., Baldessarini, R. J., Camprodon, J. A., Dougherty, D. D., Givon, L., DeVido, J., & Alpert, J. E. (2021). Psychopharmacology and Neurotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/9780511846403.015
573. Seivewright, N. (1999). Dual diagnosis – drug misuse and psychiatric disorder. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544262.011
574. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
575. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
576. Sengupta, R., Roy, S., & Bhattacharya, M. (2019). STUDY OF GENE-ENVIRONMENT CAUSES OF MAJOR DEPRESSIVE DISORDER TO STATISTICALLY DEFINE THE MOST COMMON CAUSE BEHIND IT.. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/8804
577. Sepede, G., Iorio, G. D., Sarchione, F., Fiori, F., & Giannantonio, M. D. (2017). Bupropion Augmentation in a Case of Compulsive Buying Disorder. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000232
578. Sethi, K. D. (2001). Movement Disorders Induced by Dopamine Blocking Agents. Seminars in Neurology. https://doi.org/10.1055/s-2001-13120
579. Sevarino, K. A., & Shelby, B. C. (2015). Stimulant Use Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch80
580. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
581. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
582. Shamsi, S., & Khan, S. (2019). Use of Pain Assessment Tools in Physiotherapy.
583. Sharma, M., Nagori, K., Agrawal, S., Verma, V. S., Swarnakar, H., Vaishnav, S., Nazir, M., Khan, N., & Singh, A. (2014). Drug Abuse: A Curse for Human Society. Asian Journal of Research in Pharmaceutical Sciences.
584. Sharma, S., Nepal, B., Moon, C. S., Chabenne, A., Khogali, A., Ojo, C., Hong, E., Gaudet, R., Sayed-Ahmad, A., Jacob, A., Murtuza, M., & Firlit, M. L. (2014). Psychology of Craving. Open Journal of Medical Psychology. https://doi.org/10.4236/ojmp.2014.32015
585. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
586. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
587. Shibasaki, H., & Hallett, M. (2016). Psychogenic Neurologic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190240974.003.0026
588. Shields, L. B. E., Rolf, C. M., & Hunsaker, J. C. (2015). Sudden Death Due To Acute Cocaine Toxicity—Excited Delirium in a Body Packer. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12860
589. Shiffman, S., West, R., & Gilbert, D. G. (2004). Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine & Tobacco Research. https://doi.org/10.1080/14622200410001734067
590. Shinohara, M., & Yamada, M. (2016). [Drug-induced Cognitive Impairment].. PubMed. https://doi.org/10.11477/mf.1416200415
591. Shirley, K. L., Norelli, L. J., & Smith, H. S. (2008). “Impulsology” <i>A New Paradigm for Addiction</i>. https://doi.org/10.1093/oso/9780195300550.003.0013
592. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
593. Siddiqui, J. A., Qureshi, S. F., & Ghamdi, A. K. A. (2017). Alien Abductions: A Case of Sleep Paralysis. Sleep and Hypnosis. https://doi.org/10.5350/sleep.hypn.2017.19.0144
594. Sievers, M., Sato, T., Möller, H.-J., & Bottlender, R. (2005). Obsessive-compulsive Disorder (OCD) with Psychotic Symptoms and Response to Treatment with SSRI. Pharmacopsychiatry. https://doi.org/10.1055/s-2005-837814
595. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
596. Silverstein, E., Basiru, T., Aulakh, M., Verzura, M. L., & Suarez, R. (2025). Management of Acute Onset Catatonia Postpartum in a Patient With a History of Major Depressive Disorder With Psychotic Features: A Case Report. Cureus. https://doi.org/10.7759/cureus.84392
597. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
598. Simeon, D., & Abugel, J. (2006). Diagnosing Depersonalization Disorder. https://doi.org/10.1093/oso/9780195170221.003.0005
599. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
600. Sinha, S., Moss, A. J., & Calkins, H. (2007). The etiology of sudden death. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544828.014
601. Skosnik, P. D., Sewell, R. A., García‐Sosa, I., Ranganathan, M., & D’Souza, D. C. (2010). Efeitos comportamentais, cognitivos e psicofisiológicos dos canabinoides: relevância para a psicose e a esquizofrenia. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462010000500005
602. Skosnik, P. D., Sewell, R. A., García‐Sosa, I., Ranganathan, M., D’Souza, D. C., & Ribicoff, A. (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia Efeitos comportamentais, cognitivos e psicofisiológicos de canabinoids: relevância para a psicose e esquizofrenia.
603. Smith, A. D., & Aronson, J. K. (2002). Adverse reactions to drugs. https://doi.org/10.1093/oso/9780192632340.003.0009
604. Smith, B. H., Molina, B. S. G., & Pelham, W. E. (2002). The Clinically Meaningful Link Between Alcohol Use and Attention Deficit Hyperactivity Disorder.. Alcohol Research & Health.
605. Smith, G. T., Zapolski, T. C. B., Combs, J. L., & Friend, R. E. (2010). Impulsivity. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0436
606. Smith, M. (2022). Addiction as a Sui Generis Force. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2022.13.00708
607. Smith, M. B. (2023). Addiction as a Sui Generis Force: An Opinion Overview. https://doi.org/10.9734/bpi/nramms/v3/6349a
608. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
609. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
610. Spanagel, R., Tran, B. X., Reyes‐Gibby, C. C., DeBeck, K., Ibrahim, F., & Bonevski, B. (2016). Advances in Drug Addiction.
611. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
612. Spínola, C., Santana, L., & Santos, L. (2019). COMPULSORY ADMISSIONS AFTER EMERGENCY DEPARTMENT FORCED CONDUCTION: THE ROLE OF DIAGNOSIS. https://doi.org/10.26226/morressier.5d1a036e57558b317a13ff12
613. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
614. Stahl, S. M. (2002). Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression?. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v63n1101
615. Stahl, S. M. (2006). Positive findings for negative symptoms of schizophrenia: no longer untreatable?. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2006.00904.x
616. Stahl, S. M., & Morrissette, D. A. (2018). Treatment of Secondary Behavioral Symptoms of Dementia. https://doi.org/10.1017/9781107706842.008
617. Stankewicz, H., Richards, J. R., & Salen, P. (2017). Alcohol Related Psychosis. StatPearls.
618. Stanley, R. O., & Burrows, G. D. (2001). The Negative Consequences of Hypnosis Inappropriately or Ineptly Applied. https://doi.org/10.1002/0470846402.ch23
619. Steefan, J. M., Siddesha, G., & Naveen, A. (2023). Adverse Effects of Antipsychotic Drugs - A Review. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20230916
620. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
621. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
622. Stoller, K. B. (2015). Psychiatric Co-occurring Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0015
623. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
624. Strain, J. J., Klipstein, K., & Newcorn, J. H. (2008). Adjustment Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch81
625. Stratyner, H. B. (2006). Multi-factorial Approaches to Substance Use Disorders and Addiction. CNS Spectrums. https://doi.org/10.1017/s109285290001498x
626. Sugiyama, H., & Kanba, S. (2001). [Symptomatology and diagnosis of depression].. PubMed.
627. Sumiyoshi, T., Matsuoka, T., & Kurachi, M. (2012). Role for Pituitary Neuropeptides in Social Behavior Disturbances of Schizophrenia. InTech eBooks. https://doi.org/10.5772/52326
628. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
629. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
630. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
631. Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017). Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. Mental Health Clinician. https://doi.org/10.9740/mhc.2017.07.156
632. Sáiz, P. A., G-Portilla, M., Paredes, M., Bascarán, T., & Bobes, J. (2002). Instrumentos de evaluación en alcoholismo. Adicciones. https://doi.org/10.20882/adicciones.534
633. Sánchez, L. C., Cardona, A., cordoba, S., Silva, A. V., Ruiz, A. C., Ibáñez‐Pinilla, M., Pérez-Olmos, I., & Flórez, J. (2010). Experiencias de estigma en personas con enfermedad mental y su impacto en la autoestima en Colombia. reponame:Repositorio Institucional EdocUR.
634. Taliyan, R., Singh, G., & Sharma, P. (2012). None. International Journal of Pharmaceutical Sciences and Research. https://doi.org/10.13040/ijpsr.0975-8232.3(10).3530-42
635. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
636. Taoufiq, P. I. (2024). Cognitive behavioral therapy for a case of addiction with personality disorder (clinical case study). ARID International Journal of Social Sciences and Humanities. https://doi.org/10.36772/arid.aijssh.2024.s.69
637. Taylor, M. E., & Whitney, J. (2021). Impaired Cognition and Falls. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594455.009
638. Taylor, S. M., & Beckmann, D. (2021). An adolescent with new-onset inattention. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0028
639. Telegdy, E. (2009). Trichotillomania. Orvosi Hetilap. https://doi.org/10.1556/oh.2009.28700
640. Terman, M., & Terman, J. S. (2013). Chronotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.026
641. Terçariolli, B. I., Rosa, J. M., Vieira, G. P., Cardoso, R., & Lage, P. S. (2024). RESUMO Introdução: Os transtornos mentais são definidos como sendo síndromes caracterizadas por uma perturbação clinicamente expressiva na cognição, na regulação emocional ou no comportamento de um indivíduo, que refletem uma disfunção nos processos psicológicos, biológicos ou de desenvolvimento subjacentes ao funcionamento mental. Estes estão frequentemente associados ao sofrimento ou às incapacidades. Sabe-se que uma das características marcantes de determinados transtornos está relacionada à…. Revista fisio&terapia.. https://doi.org/10.69849/revistaft/fa1020240911111905
642. Thomas, N., & Pantelis, C. (2015). Psychotic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp535
643. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
644. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
645. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
646. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
647. Tiwari, M. S. K., & Kushwaha, M. M. D. (2022). Adverse Effect of Non-Narcotic Drug on CNS and Visceral Organ. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-3081
648. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
649. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
650. Torrens, M., Martínez-Sanvisens, D., Martinez-Riera, R., Bulbena, A., Szerman, N., & Ruiz, P. (2011). Dual Diagnosis. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0b013e318215f322
651. Torrez, R. D. A., Mercado, A. N. F., Vargas, K. P. C., & Luza, P. L. (2012). Necrosis del cuerpo calloso: Síndrome de Marchiafava - Bignami. DOAJ (DOAJ: Directory of Open Access Journals).
652. Torry, Z. D., & Weiss, K. J. (2012). Medication Noncompliance and Criminal Responsibility: Is the Insanity Defense Legitimate?. SSRN Electronic Journal.
653. Torry, Z. D., & Weiss, K. J. (2012). Medication Noncompliance and Criminal Responsibility: Is the Insanity Defense Legitimate?. The Journal of Psychiatry & Law. https://doi.org/10.1177/009318531204000208
654. Touloumis, C. (2021). Treatment resistant depression: Challenges and therapeutic choices. Psychiatriki. https://doi.org/10.22365/jpsych.2021.047
655. Tranel, D., McNutt, A., & Bechara, A. (2012). Smoking Cessation After Brain Damage Does Not Lead to Increased Depression. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0b013e3182492a9c
656. Treede, R. (2017). SP0019 Signs, symptoms and co-morbidities of fibromyalgia. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-eular.7289
657. Treisman, G. J., & Clark, M. R. (2011). A Behaviorist Perspective. Advances in psychosomatic medicine. https://doi.org/10.1159/000324063
658. Trill, M. D. (2012). Psychological aspects of depression in cancer patients: an update. Annals of Oncology. https://doi.org/10.1093/annonc/mds350
659. Trivedi, M. S., Hershman, D. L., & Crew, K. D. (2015). Management of Chemotherapy-Induced Peripheral Neuropathy. American Journal of Hematology / Oncology®.
660. Trujillo, K. A. (2002). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_20
661. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
662. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
663. Tsolakis, P. (2024). Psychotherapeutic Approaches in the Treatment of Specific Phobias in Adults. https://doi.org/10.31219/osf.io/mu4x8
664. Tyler, R. E., & Leggio, L. (2024). Biological basis of addiction and alcohol use disorder. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000177
665. Ullán, M. L. G. (2015). Conciencia de enfermedad y adherencia terapéutica en el paciente psicótico. https://doi.org/10.14201/gredos.128142
666. Upadhyay, S., Elmatite, W., Taqi, S., Jagia, M., & Mallick, P. (2011). Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian Journal of Palliative Care. https://doi.org/10.4103/0973-1075.92353
667. Urakov, T., & Hart, R. (2017). Intoxicants. Routledge eBooks. https://doi.org/10.4324/9781315382760-68
668. Uysal, C., & Albayrak, Y. (2013). IMIPRAMINE INDUCED ACUTE DYSTONIA IN A CHILD WITH ENURESIS NOCTURNA.
669. Vandvik, I. H., & Skjeldal, O. H. (1994). [Conversion disorders in children and adolescents. A multidisciplinary approach].. PubMed.
670. Vanin, J. R. (2008). Brief Psychiatric History and Mental Status Examination. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-263-2_2
671. Vasconcelos, L. P. B., Gandini, J., Teixeira, A., & Manto, M. (2022). Movement Disorders Associated With Stimulants and Other Drugs of Abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0009
672. Vaswani, M. (2023). Addiction Dispelling Myths. https://doi.org/10.37871/jbres1786
673. Vataja, R., & Leppävuori, A. (2012). [Assessment and treatment of conversion disorder: the most fascinating borderline of psychiatry and neurology].. PubMed.
674. Vaz, E. C., & Amorós, R. M. (2010). Síndrome de Diógenes: A propósito de un caso. Revista de la Asociación Española de Neuropsiquiatría. https://doi.org/10.4321/s0211-57352010000300009
675. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
676. Velásquez-Martínez, M. C., & Ortíz, J. G. (2014). Abuso de Drogas: Generalidades Neurobiológicas y Terapéuticas. Actualidades en Psicología. https://doi.org/10.15517/ap.v28i117.14135
677. Vergano, S. A. S., Sluijs, P. J. V. D., & Santen, G. W. (2019). ARID1B-Related Disorder.
678. Vernier, L., Rocha, B., Razzolini, D., Bartz, D., & Vargas, G. (2014). Reports of Complaints with Tinnitus Patients: A Qualitative Study. International Archives of Otorhinolaryngology. https://doi.org/10.1055/s-0034-1389005
679. Vicente‐Rodríguez, M., Herradón, G., & Pérez‐García, C. (2021). Toxicology of Drugs of Abuse. CRC Press eBooks. https://doi.org/10.1201/9780203730584-26
680. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
681. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
682. Virmani, A., Ali, S. F., & Binienda, Z. (2010). Neuroprotective strategies in drug abuse‐evoked encephalopathy. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05171.x
683. Vk, S., Tn, S., Ln, V., Konina, & Oi, E. (1991). [Characteristics of psychopathology of tobacco dependence].. PubMed.
684. Volkow, N. D., & Wolf, A. (1991). THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.. Brookhaven National Laboratory eBooks.
685. Wahyuni, A. A. S., WIGUNA, I. G. R. P., & Aditya, M. R. (2023). WAHAM SOMATIK : SEBUAH TINJAUAN PUSTAKA. Jurnal Hasil Penelitian dan Pengembangan (JHPP). https://doi.org/10.61116/jhpp.v1i3.156
686. Wake, R., Miyaoka, T., Furuya, M., Hashioka, S., & Horiguchi, J. (2016). Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527315666160413120541
687. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
688. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
689. Walker, M., Hall, K. S., Peppercorn, K., & Tate, W. P. (2022). The significance of oxidative stress in the pathophysiology of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Medical Research Archives. https://doi.org/10.18103/mra.v10i9.3050
690. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
691. Webb, A. M. B., Ford, S. C., & Santiago, P. N. (2018). Adjustment Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190457136.003.0005
692. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
693. Weigel, G. (2014). Critical Additions Required. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0488b
694. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
695. Wenbing, C., Asano, T., Notaka, I., Shin-Ichi, M., & Nitta, A. (2025). SUPPRESSION OF TENEURIN-4 IN THE NUCLEUS ACCUMBENS ALLEVIATES METHAMPHETAMINE-INDUCED DOPAMINE RELEASE AND BEHAVIORAL ALTERATIONS IN MICE. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.174
696. Wet, E. D. (2006). Indicators of teenage drug abuse : social skills. SA pharmacist's assistant/South African pharmacist's assistant.
697. Wilson, M. P., & Vilke, G. M. (2013). The patient with excited delirium in the emergency department. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.021
698. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
699. Winkelmann, C., & Schreiber, T. (2019). Using ’White Flags’ to categorize socio-cultural aspects in chronic pain. European Journal of Public Health. https://doi.org/10.1093/eurpub/ckz186.196
700. Winstock, A., & Schifano, F. (2012). Disorders relating to the use of ecstasy and other ‘party drugs’. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0066
701. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
702. Wojtyła-Buciora, P., Grzelak, T., Giermaziak, W., Mikołajczak, R., Kapka‐Skrzypczak, L., & Mądry, E. (2023). Novel Psychoactive Substances as a Vital and Ever-Changing Concern in Public Health. https://doi.org/10.2478/bgbl-2023-0016
703. Woo, S., & Keatinge, C. (2016). Neurodevelopmental Disorders I: Autism Spectrum Disorder. https://doi.org/10.1002/9781394259472.ch4
704. Wright, C., & Burns, T. (2002). Management of serious mental illness. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508946.003.0014
705. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
706. Yan, R. M., Cardonne, M. M., Reyes, E. J. M., & Leyva, A. G. (2022). Herramienta para la obtención de Patrones de Conectividad Cerebral en Pacientes con Deterioro Cognitivo. Orange Journal. https://doi.org/10.46502/issn.2710-995x/2021.6.04
707. Yanai, K., & Hosaki, H. (1994). [Manic-depressive states induced by drugs and various diseases].. PubMed.
708. Yanti, L., Andari, F. N., Novriadi, D., & Ferasinta, F. (2022). PENURUNAN INSOMNIA PADA LANSIA DENGAN TERAPI ZIKIR. Jurnal Pengabdian Masyarakat Bumi Raflesia. https://doi.org/10.36085/jpmbr.v5i3.3859
709. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
710. Yehuda, R., Lehrner, A., & Pratchett, L. C. (2016). Trauma‐ and Stressor‐Related Disorders. https://doi.org/10.1002/9781118654231.ch13
711. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
712. Yohannes, A. M., & Baldwin, R. (2008). Medical Comorbidities in Late-Life Depression.
713. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
714. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
715. Yui, K. (2015). EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology. https://doi.org/10.2174/1570159x1306151126144423
716. Yung, A. R. (2011). Risk, Disorder and Diagnosis. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048674.2011.614926
717. Yunita, A. M., Andrianto, H. W., & Susilawati, S. (2018). Implementasi Forward Chaining untuk Identifikasi Dini Penyakit Akibat Ketergantungan Narkoba Jenis Ganja. ProTekInfo(Pengembangan Riset dan Observasi Teknik Informatika). https://doi.org/10.30656/protekinfo.v5i0.1027
718. Yunita, A. M., Andrianto, H. W., & Susilawati, S. (2018). Implementasi Forward Chaining untuk Identifikasi Dini Penyakit Akibat Ketergantungan Narkoba Jenis Ganja. ProTekInfo(Pengembangan Riset dan Observasi Teknik Informatika). https://doi.org/10.30656/protekinfo.v5i0.1028
719. Yutzy, S. H. (2015). Somatic Symptom and Related Disorders: Somatic Symptom Disorder, Illness Anxiety Disorder, and Conversion Disorder. Psychiatry. https://doi.org/10.1002/9781118753378.ch62
720. Zagorski, N. (2022). Misuse of Steroids, Other Performance Enhancers Slips Under Radar. Psychiatric News. https://doi.org/10.1176/appi.pn.2022.03.10.42
721. Zeller, J. L., Burke, A. E., & Glass, R. M. (2008). Acute Pain Treatment. JAMA. https://doi.org/10.1001/jama.299.1.128
722. Zolas, P. T., & Sher, A. (2013). Antipsychotic drugs: A review with a focus on QT prolongation. Journal of Pharmacy and Alternative Medicine.
723. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
724. Zúñiga, R. L. (2017). Delirium y la presencia de respuesta inflamatoria sistémica, descontrol glucémico e hipoxia en pacientes mayores de 65 años en el servicio de urgencias médicas del Hospital General de Pachuca..
725. Ďurdík, P., Olek, F., ov, U. J., an, T. T., & Bánovčin, P. (2020). Young and exhausted. Authorea (Authorea). https://doi.org/10.22541/au.159294140.04360533
726. Šostar, Z., Vodanović, M., Breitenfeld, D., Breitenfeld, T., Buljan, D., & Granić, R. (2009). Composers - Substance Abusers. Alcoholism and psychiatry research Journal on psychiatric research and addictions.
727. Оstroumova, Т. М., & Tolmacheva, V. A. (2022). Drug-induced tremor. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2022-2-4-10
728. Оstroumova, Т. М., Kulikova, M., & De, V. (2022). Drug-induced hypertension. Medical alphabet. https://doi.org/10.33667/2078-5631-2022-3-8-13